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 Human papillomaviruses (HPVs) are involved in the pathogenesis of different 
types of human cancers, especially cancer of the cervix (CaCx). MicroRNAs (miRNAs) 
are post-transcriptional gene regulators that have recently been associated with many 
types of cancers. We analyzed the expression of cellular miRNAs in HPV-16 positive 
cervical cell lines and tissues via microarray, Northern blotting, and quantitative RT-
PCR. Three miRNAs were overexpressed and 24 underexpressed in cervical cell lines 
containing integrated HPV-16 DNA compared to the normal cervix. An HPV-negative 
CaCx cell line, C-33A, showed underexpression of four miRNAs compared to the 
normal cervix. Also, nine miRNAs were overexpressed and only one underexpressed in 
cell lines containing integrated HPV-16 DNA compared to C-33A. MicroRNA-218 (miR-
218) was specifically underexpressed in cell lines, cervical lesions and cancer tissues 
containing integrated HPV-16 DNA compared to both C-33A and the normal cervix. 
Exogenous expression of the HPV-16 E6 oncogene reduced miR-218 expression, and 
conversely, RNA interference of E6/E7 oncogenes in an HPV-16 positive cell line 
increased miR-218 expression. Furthermore, exogenous expression of miR-218 in 
HPV-16 positive cell lines decreased expression of the epithelial-specific gene LAMB3, 
which is involved in cell migration and tumorigenicity.  
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We analyzed the expression of cellular miRNAs in additional clinical samples 
including six HPV-16 positive cervical cancers, three cervical dysplasias, and four 
normal cervical tissues using TaqMan® MicroRNA Arrays V2.0. Eighteen miRNAs were 
overexpressed and two underexpressed in cervical cancer tissues compared to normal 
cervical tissues. Nine miRNAs were consistently overexpressed, and two miRNAs were 
consistently underexpressed, including miR-218, in cervical dysplasias and cervical 
cancer tissues compared to normal tissues. We also found that exogenous expression 
of miR-218 in HPV-16 positive cell lines decreased expression of the extracellular 
matrix protein MMP3, which is involved in the epithelial-mesenchymal transition.  
We also demonstrated that HPV-16 E6 regulates miR-218 via the histone 
acetyltransferase p300 in cervical cells. The expression of miR-218 was found to be 
reduced in HPV-negative cells upon p300 knock-down or p300 inhibition with anacardic 
acid, and expression of miR-218 was reactivated in HPV-16 positive cells upon EZH2 
knock-down or inhibition with adenosine dialdehyde. Reactivation of miR-218 was 
enhanced upon treatment with a combination of 5-azacytidine, trichostatin A, and 
adenosine dialdehyde. We also demonstrated that miR-218 reduces the migration and 
invasion of SiHa cervical cancer cells, indicating that miR-218 functions as a tumor 
suppressor in cervical cancer and that it may have therapeutic value. 
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1.0  CHAPTER 1 
GENERAL INTRODUCTION 
 2 
1.1 HUMAN PAPILLOMAVIRUS BIOLOGY 
Human papillomaviruses (HPVs) are common papilloma (wart)-causing viruses 
of the Family Papillomaviridae. They are responsible for inducing a variety of cutaneous 
and mucosal lesions and importantly are the cause of cervical cancer (Walboomers et 
al., 1999) (Greenlee et al., 2001). In addition, recent molecular epidemiologic studies 
have shown a strong correlation between oncogenic HPV infections and a subset of 
oropharyngeal cancers (Gillison et al., 2000) (Wong and Munger, 2000). HPV DNA can 
be found in 99.7% of cervical cancers and 25% of oropharyngeal cancers (Greenlee et 
al., 2001) (Gillison et al., 2000). Although prophylactic vaccines have been approved by 
the FDA, cervical cancer remains a threat for the millions of women infected with genital 
HPVs. The current vaccines protect against two high-risk HPVs (types 16 and 18), 
which account for approximately 70% of cervical cancers. The length of protection 
offered by the vaccines is currently unknown. 
More than 100 HPV types exist, and they can be grouped as low-risk (LR) or 
high-risk (HR) based on the risk of malignant transformation (de Villiers et al., 2004). 
LR-HPVs, such as HPV-6 and 11, are associated with epithelial lesions, while HR-
HPVs, such as HPV-16 and 18, are associated with cancer (de Villiers et al., 2004). 
HPVs are small circular non-enveloped double-stranded (ds) DNA viruses (Hebner and 
Laimins, 2006). The ~8000 base pair (bp) genome of HPVs encodes eight open reading 
frames (ORFs), which are designated as either early (E) or late (L) according to their 
temporal expression (Hebner and Laimins, 2006). Polycistronic transcripts are 
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processed by alternative splicing and translated by ribosomal scanning (Watt, 1998). 
Early in infection, the non-structural genes E1, E2, E4, E5, E6, and E7 are expressed 
(Watt, 1998). The E1 helicase and E2 transcription factor cooperate to mediate efficient 
viral replication, and the E6 and E7 oncogenes work synergistically to deregulate cell 
cycle controls (Watt, 1998). Viral genomes are maintained episomally in low-copy 
numbers at this stage (Watt, 1998). Upon terminal differentiation, the late structural 
genes L1 and L2 are expressed, coinciding with a burst of viral replication and 
transcription, and virions may then be shed and infect additional tissues (Watt, 1998).   
The E6 protein interacts with the tumor suppressor protein p53 (Werness et al., 
1990) as a tripartite complex with the E6-associated protein (E6AP) (Huibregtse et al., 
1991). This interaction results in ubiquitination and degradation of p53 (Scheffner et al., 
1990). E7 interacts with the tumor suppressor protein Rb, preventing its interaction with 
E2F and thereby allowing constitutive expression of E2F-mediated genes (Chellappan 
et al., 1992). Persistent infections with HR-HPVs, such as HPV-16, are often 
characterized by integration of the viral genome into the host chromosomes, which 
results in increased expression of the E6 and E7 oncogenes due to interruption of the 
E2 regulatory gene. Integration is thought to occur at fragile sites in chromosomes 
(Thorland et al., 2003) and may be a consequence of HR-HPV E6/E7-induced 
chromosomal instability. The disruption or amplification of centrosomes occurs in most 
cancers, making chromosomal instability a hallmark of cancer. HR-HPV E6 and E7 can 
cooperate to induce centrosome abnormalities and genomic instability (Duensing et al., 
2000). Although HR-HPV E6 and E7 are sufficient to immortalize human keratinocytes 
in vitro (Munger et al., 1989), additional factors are required for progression to cancer. 
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The activation of oncogenes such as H-ras and the expression of the catalytic subunit of 
telomerase (hTERT) are also required for transformation of primary human epithelial 
cells (Hahn and Weinberg, 2002).  
 5 
Figure 1. Human Papillomavirus Organization and Life Cycle. (A) Episomal HPV DNA. 
In most cases of cervical cancer, the virus integrates into the host DNA. (B) Upon 
microabrasion, HPV particles infect the basal cells of the epithelium. As the cells divide, 
the infection expands laterally. Viral early genes are expressed and the genomes 
replicate. One daughter cell migrates into the suprabasal layer and undergoes 
differentiation, during which the virus enters the productive phase of its life cycle. Viral 
DNA replication/amplification, late gene expression, and capsid protein assembly occur. 
Viral particles are released at the surface of the epithelium (Woodman et al., 2007). 
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1.2 HUMAN PAPILLOMAVIRUS E6/E7 ONCOGENES AND CERVICAL CANCER 
Cervical cancer is the second-highest cancer-related cause of death among 
women worldwide, with an estimated yearly mortality of 250,000 (Walboomers et al., 
1999). In the United States, there are approximately 750,000 new cases of HPV 
infection every year, including about 4,000 cases of invasive cervical cancer, resulting in 
nearly 5,000 deaths per year.  More importantly, there are approximately 2 million cases 
of premalignant HPV lesions annually. In general, 5-40% of sexually active teenagers 
and adults harbor genital HPV infections, depending on the population group. HPVs 
represent the most common sexually transmitted disease in the United States. It is 
estimated that more than 50% of all sexually active women in the U.S. will be infected 
with HPVs at some point during their lifetime. 
HPV-16 E6 contributes to cellular transformation through various protein 
interactions. The E6 protein binds p53 (Werness et al., 1990) in a tripartite complex with 
E6AP (Huibregtse et al., 1991). This results in the ubiquitination and degradation of p53 
(Scheffner et al., 1990). E6 binding of p300/CBP prevents p53 acetylation, (Patel et al., 
1999) (Zimmermann et al., 1999), further preventing p53-mediated transcription and 
increasing proliferation. Interaction with E6AP and transcription factors NFX123, Sp1, 
and Myc activates hTERT expression, preventing telomere shortening and promoting 
immortalization (Howie et al., 2009). Degradation of PDZ proteins induces hyperplasia 
through loss of cell polarity (Nguyen et al., 2003) (Thomas et al., 2008). Degradation of 
pro-apoptotic protein BAX and BAK inhibits apoptosis (Garnett et al., 2006), as does 
 7 
interaction with FADD and Caspase 8 (Filippova et al., 2004) (Garnett et al., 2006). 
Binding to focal adhesion kinase (FAK) and paxillin promote anchorage-independent 
growth (McCormack et al., 1997) (Tong and Howley, 1997).  
HPV-16 E7 bypasses G1-S arrest and induces proliferation through interaction 
and inhibition of pRB family members and constitutive activation of E2F-responsive 
genes (Dyson et al., 1989) (Chellappan et al., 1992). E7 also inhibits cyclin-dependent 
kinase inhibitors p21 and p27, stimulating cyclins and activating CDK2 (Zerfass-Thome 
et al., 1996) (He et al., 2003). E7 can bind HDACs on some promoters to repress 
transcription and facilitate HDAC removal at others to activate transcription (Brehm et 
al., 1998) (Brehm et al., 1999). E7-induced DNA damage activates the ATM-ATR 
pathway leading to genomic instability (Moody and Laimins, 2009). 
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Figure 2. Human papillomavirus E6/E7 interactions. (A) Cellular protein interactions of 
HPV-16 E6. (B) Cellular protein interactions of high-risk HPV-16 E7. (Moody and 
Laimins, 2010) 
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1.3 MICRORNA BIOLOGY 
MicroRNAs are a recently characterized class of gene regulators. Mature 
miRNAs are ~22 nt single-stranded non-protein-coding RNAs that negatively regulate 
their targets. MiRNAs function by binding to the 3’ UTRs of target messenger (m)RNAs 
thereby mediating either translational repression or mRNA destruction. MiRNAs were 
first discovered in C. elegans (Lee et al., 1993). They have since been found to be 
conserved across many species, and may regulate thousands of targets via the RNAi 
pathway (Lewis et al., 2005). 
Most miRNAs are transcribed by RNA polymerase II, have a Cap, and are 
polyadenylated (Lee et al., 2004) (Cai et al., 2004). They are often processed from 
polycistronic transcripts (Lee et al., 2002). Following transcription, the large primary-
miRNA transcripts are processed into precursor-miRNAs by the protein Drosha (Lee et 
al., 2003). Pre-miRNAs are hairpin-like structures with characteristic 2 nt 3’ overhangs. 
They are exported to the cytoplasm by exportin 5 (Lund et al., 2004), where further 
processing into miRNA duplexes by the protein Dicer occurs (Hutvagner et al., 2001). 
MiRNA duplexes associate with the RISC complex but only one strand, the mature 
miRNA, remains associated with it and is delivered to its target (Schwarz et al., 2003) 
(Khvorova et al., 2003). The fate of target mRNAs depends on the degree of 
complementarity with the miRNA. Commonly, the 5’ 2-8 nt of the miRNA (called the 
seed sequence) is complementary to the target, and the remaining miRNA contains 
many mismatches. A low degree of complementarity results in translational repression, 
 10 
whereas a high degree of complementarity results in cleavage of the mRNA followed by 
its eventual destruction (Kim, 2005). Other classes of small RNAs that function to 
repress mRNA have recently been described. (Li et al., 2009) 
 11 
Figure 3. MiRNA biogenesis. Primary microRNA transcripts are transcribed by RNA 
Polymerase II. They may be transcribed independently or excised from the introns of 
protein-coding genes. Pri-miRNAs are then processed into precursor hairpin molecules 
by Drosha/DGCR8. Following export to the cytoplasm, pre-miRNAs are further 
processed to yield ~22 nt single-stranded mature miRNAs. The mature miRNAs, 
incorporated into the RNA-induced silencing complexes (RISCs) then bind to the 3’UTR 
of mRNAs, causing mRNA degradation or translational repression. 
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1.4 MICRORNAS AND CERVICAL CANCER 
Distinct miRNA expression profiles have been linked to many cancers (Volinia et 
al., 2006). MiRNA coding sequences are often found near fragile sites in chromosomes, 
as well as near integration sites of HR-HPVs (Zhang et al., 2006). MiRNAs can serve as 
oncogenes or tumor suppressors. The first miRNA genes shown to be associated with 
cancer were miR-15 and miR-16. These two miRNAs are usually downregulated in 
chronic lymphocytic leukemia (CLL) (Calin et al., 2002). They have recently been shown 
to negatively regulate Bcl-2, an oncogene that is commonly overexpressed in many 
cancers (Cimmino et al., 2005). These miRNAs are transcribed as a cluster within the 
intron of a non-protein coding gene Leu2 that is often deleted in CLL. The let-7 family of 
miRNAs regulates the Ras oncogenes (Johnson et al., 2005). Ras genes contain 
activating mutations in approximately 15%-30% of cancers. The miRNAs controlling the 
expression of these oncogenes therefore serve as important regulators of cellular 
proliferation. Some cancers have shown downregulation of let-7 family miRNAs 
resulting in reciprocal upregulation of Ras. This downregulation is most pronounced in 
lung cancers (Takamizawa et al., 2004), but is sporadically regulated in other tissues 
(Johnson et al., 2005).  
Oncogenes and tumor suppressors can also regulate the expression of miRNAs. 
C-myc regulates the miRNA cluster miR-17-92 that in turn targets E2F1 (O'Donnell et 
al., 2005). Upregulation of this cluster was demonstrated for B cell lymphomas (He et 
al., 2005). C-myc is often upregulated in cancers, and it serves as a transcription factor 
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for the miR-17-92 cluster (O'Donnell et al., 2005). Because C-myc directly targets E2F1, 
the C-myc-mediated repression of E2F1 via the miR-17-92 cluster serves to fine-tune its 
regulation (O'Donnell et al., 2005). Several studies have shown that p53, a major target 
of E6, is involved in the transcription and expression of many miRNAs (Xi et al., 2006). 
Methylation also plays a role in the regulation of miRNA expression (Saito et al., 2006) 
(Brueckner et al., 2007) (Lujambio et al., 2007). Changes in the expression of Dicer and 
other miRNA machinery proteins have been reported as well (Chiosea et al., 2006) 
(Chiosea et al., 2007). Many of the cell growth and proliferation pathways affected by 
HPV-16 contain probable targets or mediators of cellular miRNAs.  
In cervical cancer, our studies showed that miR-218 is significantly 
underexpressed in HPV-16 positive cervical cancer cell lines and tissues (Martinez et 
al., 2008). Wang et al. found miR-15b, miR-16, miR-146a, and miR-155 to be most 
highly overexpressed in cervical cancer tissues and miR-126, miR-143, and miR-145 to 
be most underexpressed (Wang et al., 2008). They also found that miR-21, miR-181c, 
and miR-223 were overexpressed and miR-218 was underexpressed (Wang et al., 
2008). Lui et al. analyzed the respective cloning frequency of miRNAs in cervical 
carcinoma cell lines versus normal cervical tissue (Lui et al., 2007). They did not amplify 
miR-218 in any of the HPV-positive cells. They further evaluated the expression levels 
of miR-21 and miR-143 and found significant overexpression of miR-21 and 
underexpression miR-143 in cervical cancer cell lines and tissues versus normal 
cervical tissue (Lui et al., 2007). Lee et al. analyzed 157 cellular miRNAs via the 
TaqMan® MicroRNA Human Early Panel Kit (Applied Biosystems) in 10 cervical cancer 
specimens and 10 normal cervical specimens (Lee et al., 2008). They found 
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overexpression of 68 miRNAs and underexpression of two miRNAs. They found that the 
10 miRNAs that were most highly overexpressed were miR-199-s, miR-9, mir-199*, 
miR-199a, miR-199b, miR-145, miR-133a, miR-133b, miR-214, and miR-127.  Only two 
miRNAs (miR-149 and miR-203) were found to be underexpressed (Lee et al., 2008).  
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Figure 4. MiRNAs and cancer. Loss of or low expression of miRNAs that target 
oncogenes may contribute to a cancer phenotype. High expression of miRNAs that 
target tumor suppressors may also lead to the cancer phenotype. (Garzon et al., 2006) 
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2.0  CHAPTER 2 
HUMAN PAPILLOMAVIRUS TYPE 16 REDUCES THE EXPRESSION OF 
MICRORNA-218 IN CERVICAL CARCINOMA CELLS 
 
Work described in this section was published in Oncogene (Oncogene. 2008, 27:2575-
82) with authors Amy S. Gardiner, Ivan Martinez, Kathryn F. Board, Federico A. 
Monzon, Robert P. Edwards, and Saleem A. Khan. A.S. Gardiner and I. Martinez 
contributed equally to this work. 
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2.1 INTRODUCTION 
High-risk human papillomaviruses (HPVs) such as types 16 and 18 are causally 
involved in cervical cancer (zur Hausen, 2002). HPVs are small double-stranded DNA 
viruses that contain two oncogenes E6 and E7 that are involved in cellular 
transformation. Most low grade cervical lesions contain HPV DNA in an episomal state, 
but in most cases of cervical carcinomas the HPV DNA is found integrated into the host 
chromosomes, increasing expression of E6 and E7 (Munger and Howley, 2002) 
(Hebner and Laimins, 2006). The E6 protein promotes ubiquitination and proteasomal 
degradation of the tumor suppressor protein p53 (Huibregtse et al., 1991) (Lechner et 
al., 1992) (Band et al., 1993) (Thomas et al., 1999) and PDZ domain-containing disc 
large protein (DLG) (Gardiol et al., 1999). The E7 protein binds to and inactivates the 
function of the pRB and related tumor suppressor proteins p107 and p130 (Munger and 
Howley, 2002). E7 also interacts with additional cellular proteins such as TBP, histone 
H1 kinase and cyclin E (Massimi et al., 1996) (Hebner and Laimins, 2006). In addition, 
E6/E7 expression promotes chromosomal instability, foreign DNA integration and other 
mutagenic events in the cell (Duensing et al., 2000) (Hebner and Laimins, 2006). 
MicroRNAs (miRNAs) are small non-coding RNAs that may regulate thousands 
of mRNA targets, for reviews, see (Lewis et al., 2005) (Calin and Croce, 2006b). 
MiRNAs are transcribed in the nucleus and after processing they associate with the 
RISC complex and act as negative regulators of gene expression by binding to their 
complementary mRNA targets and either repressing translation or promoting mRNA 
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degradation (Kim, 2005). Recently, changes in the expression of miRNAs have been 
shown to be associated with a variety of human cancers (Calin and Croce, 2006a). 
In this study, we demonstrate differential expression of several miRNAs in HPV- 
16 positive cervical cell lines and tissues, as well as in the HPV-18 positive cell line 
HeLa, compared to the normal cervical tissue and an HPV-negative cervical carcinoma 
cell line. We also demonstrate that miR-218 and the tumor suppressor gene SLIT2 are 
specifically downregulated in several HPV-16 positive cervical cell lines and tissues, 
and this effect is mediated by the E6 oncogene of high-risk HPV-16. Finally, our studies 
show that LAMB3 is a possible target of miR-218 at the transcriptional level. 
2.2 MATERIALS AND METHODS 
Cell lines 
 
Cervical cancer cell lines CaSki, SiHa (HPV-16 positive), HeLa (HPV-18 
positive), and C-33A (HPV-negative) and their growth conditions have been described 
(Meissner, 1999). Three clonal populations of the HPV-16 cervical cell line W12, 20863 
(episomal HPV-16), 20861 and 201402 (integrated HPV-16), were obtained from the 
laboratories of Drs. Margaret Stanley and Paul Lambert (Medical Research Council, UK 
and University of Wisconsin, USA, respectively). The cell lines U2OS-Neo, U2OS-E6, 
U2OS-E7 (Duensing et al., 2000) were obtained from Dr. Stefan Duensing (University of 
Pittsburgh, USA). Normal oral keratinocytes (NOK) cell lines immortalized by hTERT 
expression and expressing the E6 gene of HPV-6 or HPV-16 (Piboonniyom et al., 2003) 
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were obtained from Drs. Stefan Duensing and Karl Munger (Harvard University). 
 
Cervical tissues characteristics 
 
Human cervical tissue samples were collected under an IRB approved protocol 
from patients with cervical preinvasive neoplasia undergoing leep excision or radical 
hysterectomy for invasive cervical cancer. Informed consent was obtained from all 
subjects. Parallel specimens of the same site were stained (Hemotoxylin and Eosin) to 
confirm the diagnosis. HPV-16 positivity was confirmed by RT-PCR. Total RNA from 
normal human cervix was obtained from a pool of 2 different donors (Stratagene). Prior 
to further RNA purification, these preparations contained limited levels of cellular DNA 
and were used to confirm the absence of HPV DNA. PCR amplification showed positive 
results for G3PDH and negative results for several HPV types using the degenerate 
MY09/MY11 primer pair (Manos et al., 1994). Furthermore, the preparations also did not 
give any PCR signals for the HPV-16 E7 and E2 genes. CaSki cells were used as a 
positive control and gave positive signals for the G3PDH gene as well as for the HPV L1 
gene and HPV-16 E7 and E2 genes (data not shown). 
 
MicroRNA microarray analysis 
 
Total RNA was extracted using the Ultraspec™ RNA isolation system (BIOTECX, 
USA) according to the manufacturer’s instructions. Total RNA from cell lines and normal 
cervix was used to isolate small RNAs (<200 nt) which includes miRNAs using the 
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RNeasy Mini Kit and the MinElute Cleanup Kit (Qiagen, USA). MirVana miRNA Bioarray 
(Ambion, USA) was used to analyze miRNA expression in cervical cell lines. The 
Bioarray consist of 662 probes (~22 nt long antisense oligonucleotides) that include 
known human miRNAs (328), theoretical human microarrays known as ambi-miRs (152) 
as well as unique miRNAs from mouse (114) and rat (46). Each array contains probes 
for all miRNAs in quadruplicate, and the signals obtained for each miRNA is 
represented as an average of these four values. The enriched small RNA fractions 
obtained from 25 μg of total RNA were fluorescently labeled and hybridized to the 
Bioarrays according to the manufacturer’s instructions (Ambion, USA). Each experiment 
was done twice. The Bioarrays were scanned using GenePix 4000B Scanner and the 
median fluorescent intensity was obtained after subtracting the background using the 
GenePix Pro 6.0 software. To identify differential miRNA expression between samples, 
the median fluorescent intensities were log2 transformed and normalized using the 
median within the array and the global mean adjustment among arrays using the GEDA 
program (http://bioinformatics.upmc.edu/Help/GEDADescription.html). After 
transformation and normalization, we used the Significance Analysis of Microarray 
(SAM) program version 1.21 (www-stat.stanford.edu/~tibs/SAM/) to obtain the 
differential expression profiles. 
 
MicroRNA Northern blot analysis 
 
Enriched miRNA fractions obtained from 25 μg of total RNA were separated on 
15% urea-containing polyacrylamide gels, transferred onto GeneScreen Plus 
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membranes and hybridized to 32P-labeled oligonucleotide probes complementary to 
various cellular miRNAs. We hybridized a probe complementary to the housekeeping 
splicing-related small U6 RNA for loading control. Hybridization was carried out 
overnight at 50C and the membranes were subjected to autoradiography at -80C. 
 
MicroRNA and mRNA real-time quantitative RT-PCR analysis 
 
DNase I-treated total RNA (10 ng) was subjected to qRT-PCR analysis using the 
TaqMan® miRNA Reverse Transcription Kit and miRNA Assays (Applied Biosystems, 
USA), and the Real-Time thermocycler iQ5 (BioRad, USA). The small nucleolar RNU43 
was used as the housekeeping small RNA reference gene. For qRT-PCR analysis of 
SLIT2 and LAMB3 mRNAs, the following primers were used: (SLIT2, forward 5’- 
CTGTGAATGCAGCAGTGGAT-3’ and reverse 5’-TTGTTTGGCAAGCAGCATAG-3’ 
(116-bp product); LAMB3, forward 5’- GGGAGACCATGGAGATGATG-3’and reverse 5’-
ACACGCTTCTCCAGTCCTGT-3’ (112-bp product). Also, 500 ng of total RNA from the 
cervical samples was amplified using the one step QuantiTect SYBR Green RTPCR 
Master Mix (Qiagen, USA). The primer sequences for the control housekeeping 
glyceraldehyde-3-phosphate dehydrogenase gene (G3PDH) have been described 
previously (Martinez et al., 2007). All reactions were done in triplicate and relative 
expression of RNAs was calculated using the 2 delta CT method (Livak and Schmittgen, 
2001). 
 
HPV-16 E6 and E7 siRNA and transfection assays 
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Double-stranded small interfering RNAs (siRNAs) against HPV-16 E6 (siRNA 
209, 5’-UCCAUAUGCUGUAUGUGAUTT-3’; complementary to HPV-16 positions 277 to 
298) and E7 (E7 siRNA, 5’-CCAUCUAUUUCAUCCUCCUTT-3’, complementary to 
HPV-16 positions 662 to 682) (Jiang and Milner, 2002) (Tang et al., 2006) were 
obtained from Dharmacon, USA. BLOCK-iT fluorescent double-stranded oligo (with no 
human homologous sequence) was used as a negative control as well as to measure 
the transfection efficiency (Invitrogen, USA). MiR-218 was expressed in cell lines by 
transfecting with a pre-miR-218 precursor molecule (Ambion, USA). Cell lines were 
seeded (1.5 X 105) into 6-well plates, and after 24 hr, transfected (125 nM per well of 
HPV siRNAs or 100 nM of miR-218 precursor molecule) using Lipofectamine 2000 
(Invitrogen, USA) according to the manufacturer’s instructions. Cells were harvested 
after 72 hr, and RNA and protein extractions were performed. 
 
Western blot analysis 
 
Twenty micrograms of total cellular proteins were separated on 7.5% SDS 
polyacrylamide gels, transferred to Immobilon-P PVDF membranes (Millipore), and 
incubated with primary murine monoclonal antibody (Calaluce et al., 2004) against the 
β3 chain of laminin-5 (Kalinin B1; BD Biosciences, USA). The membranes were 
subsequently incubated with a 1:5,000 dilution of the secondary anti-mouse horseradish 
peroxidase antibody (Amersham Biosciences, USA). Specific proteins were detected 
using chemiluminescence with ECL Plus Western Blotting Detection Reagents 
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(Amersham Biosciences, USA). Murine monoclonal antibody against G3PDH 
(Chemicon) was used to demonstrate equal loading. 
2.3 RESULTS 
Differential expression of microRNAs in cervical cell lines compared to the normal cervix 
and the HPV-negative cell line C-33A 
 
MiRNA microarray analysis showed that approximately 220 known human 
miRNAs out of 328 represented on the array were expressed in the normal cervix 
(Supplementary Table 1). The miRNAs that were most highly expressed in the cervix 
were miR-145, miR-26a, miR-99a, let-7a, miR-143, let-7b, let-7c, miR-125b, miR-126, 
and miR-195 in that order. We investigated the miRNA expression profile in normal 
cervical tissue and cervical carcinoma cell lines SiHa and CaSki containing integrated 
HPV-16 DNA. We also used two clonal derivatives, 20861 and 201402, of the W12 cell 
line derived from a low-grade CIN I lesion (Stanley et al., 1989), which contain 
integrated HPV-16 DNA (Alazawi et al., 2002). SAM analysis of the array data showed 
that 24 miRNAs, including miR-126, miR-143, miR-145 and miR-195 (four of the ten 
most highly expressed miRNAs in the normal cervix) were underexpressed in all the 
integrated HPV-16 cervical cell lines compared to the normal cervix (Table 1). Only 
three miRNAs, miR-182, miR-183 and miR-210, were found to be overexpressed in the 
integrated HPV-16 cell lines (Table 1). The array data for individual cell lines compared  
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Table 1. MiRNAs differentially expressed in HPV-16 positive cell lines compared to the 
normal cervix 
  
HPV-16 
integrated 
MiRNA Folda 
Overexpressed  
hsa_miR_210 7.3 
hsa_miR_182 6.4 
hsa_miR_183 5.1 
Underexpressed  
hsa_miR_126 -14.5 
hsa_miR_145 -14.1 
hsa_miR_451 -11.3 
ambi_miR_7029 -9.5 
hsa_miR_195 -8.3 
hsa_miR_143 -8 
hsa_miR_199b -7.9 
hsa_miR_133a -7.6 
hsa_miR_368 -7.6 
hsa_miR_1 -7.2 
hsa_miR_495 -6.3 
hsa_miR_497 -6.2 
hsa_miR_133b -6 
hsa_miR_223 -5.4 
hsa_miR_146a -5.1 
hsa_miR_218 -4.8 
hsa_miR_126_AS -4.7 
hsa_miR_150 -4.4 
hsa_miR_376a -4.2 
hsa_miR_214 -4.1 
hsa_miR_487b -4.1 
hsa_miR_10b -3.9 
ambi_miR_5021 -3.6 
ambi_miR_7070 -3.5 
aMean fold-changes in HPV-16 integrated  
cell lines CaSki, SiHa, 20861 and 201402.  
The q value of all miRNAs was 0. 
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Table 2. MiRNAs differentially expressed in HPV-16 positive cell lines compared to the 
HPV-negative cell line C-33A 
  
HPV-16 
integrated 
MiRNA Folda 
Overexpressed  
hsa_miR_200c 27.9 
hsa_miR_203 23.4 
hsa_miR_193b 21.2 
hsa_miR_34a 10.4 
hsa_miR_31 8.4 
hsa_miR_210 5.7 
hsa_miR_27a 5.4 
hsa_miR_503 5.4 
hsa_miR_27b 4.9 
Underexpressed  
hsa_miR_218 -7.4 
aMean fold-changes in HPV-16 integrated  
cell lines CaSki, SiHa, 20861 and 201402.  
The q value of all miRNAs was 0. 
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to the normal cervix is presented in Supplementary Table 2. In the 20863 cell line (a 
clonal derivative of the W12 cell line) containing episomal HPV-16 DNA, six miRNAs  
were underexpressed compared to the normal cervix (Supplementary Table 2). A direct 
comparison of the miRNA expression profiles of integrated vs. episomal HPV-16 cell 
lines did not reveal any significant differences (data not shown). This, at least in part, 
may result from the use of only one cell line containing episomal HPV-16 DNA, as well 
as the use of a 2-fold cut-off value and a q value of zero in our statistical analysis. 
MicroRNA expression profile of the HPV-18 containing HeLa cell line showed 
that 14 miRNAs were underexpressed in HeLa cells compared to the normal cervix 
(Supplementary Table 3). Eight of these miRNAs (miR-1, miR-133b, miR-143, miR-145, 
miR-214, miR-368, miR-451 and miR-7029) were also found to be underexpressed in 
cell lines containing integrated HPV-16 DNA (Table 1). Thirteen miRNAs were found to 
be overexpressed in the HeLa cell line compared to the normal cervix (Supplementary 
Table 3). Of these, two miRNAs (miR-182 and miR-183) were also overexpressed in the 
HPV-16 integrated cell lines (Table 1).  
Nine miRNAs in cell lines containing integrated HPV-16 DNA were found to be 
expressed at much higher levels compared to the HPV-negative cervical carcinoma cell 
line C-33A cells (Table 2). Interestingly, miR-218 was the only miRNA that was 
underexpressed in the cell lines containing integrated HPV-16 DNA as compared to 
both the normal cervix and C-33A (Tables 1 and 2). This suggested that miR-218 may 
be specifically affected in the presence of HPV-16. The array data for individual cell 
lines compared to C-33A is presented in Supplementary Table 4.  
The HPV-18 positive HeLa cell line showed overexpression of six miRNAs 
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compared to the HPV-negative cell line C-33A (Supplementary Table 5). Of these, three 
miRNAs (miR-31, miR-34a and miR-193b) were also overexpressed in integrated HPV- 
16 cell lines compared to C-33A (Table 2). Finally, the array data for the HPV-negative 
cell line C-33A showed that 4 miRNAs (miR-143, miR-145, miR-200c and miR-203) 
were underexpressed as compared to the normal cervix (Supplementary Table 6). In 
addition, qRT-PCR and Northern blot analyses showed that miR-193b, miR-205 and 
miR-497 were also downregulated in the C-33A cell line compared to the normal cervix 
(see below). 
 
Validation of the miRNA microarray expression data by quantitative real-time RT-PCR 
and Northern blot analyses 
 
The miRNA microarray results were validated by qRT-PCR and Northern blot 
analyses of 8 representative miRNAs representing those whose expression was either 
most affected, was known to be affected in other types of cancers, or one that appeared 
to be HPV-specific (miR-218) (Figure 5A, B). MicroRNAs 143, 145, 218, 368 and 497 
which were found to be downregulated in HPV-16 positive cell lines in array data were 
also found to be underexpressed based on qRT-PCR and Northern blot analyses 
(Figure 5A, B), although there were differences in the relative levels of individual 
miRNAs in various cell lines. The fold-changes observed by qRT-PCR and Northern blot 
analyses were much greater than those obtained with the microarrays. This was 
observed consistently and suggests that the results of qRT-PCR and Northern blot 
analyses are more robust for quantifying differential expression of miRNAs. The qRT-  
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Figure 5. Confirmation of miRNA microarray expression data in various cervical cell 
lines and normal cervical tissue. (A) Northern blot analysis. The housekeeping splicing-
related small U6 RNA was used as a loading control. (B) Real-time qRT-PCR analysis. 
RNU43 served as the endogenous control for miRNAs. 
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PCR and Northern blot analyses revealed that miR-200c and 205 were upregulated in 
all the HPV-positive cell lines except SiHa compared to the normal cervix (Figure 5A, 
B). These two miRNAs were not detectable in SiHa and the HPV-negative cell line C-
33A (Figure 5A, B). The “band” seen in the Northern blot for miR-368 in the 20861 
sample is a gel artifact and does not represent a miRNA signal. 
The array data obtained with the HPV-18 positive HeLa cell line were also 
validated by Northern blot and qRT-PCR analyses of three miRNAs, miR-143, miR-145, 
and miR-218 all of which were found to be downregulated by the various techniques 
(Supplementary Figure 1). 
 
MicroRNA 218 is also underexpressed in HPV-16 positive cervical lesions and cervical 
cancer tissues 
 
We also analyzed the expression profile of six representative miRNAs (all of 
which were also used for the validation of the array data for the cell lines) in three HPV-
16 positive cervical intraepithelial neoplasia grade III (CIN III) tissues and five HPV-16 
positive cervical cancer tissues (CaCx) by qRT-PCR analysis. Due to the limited amount 
of RNA available from the tissues, miRNA microarray analysis could not be done. The 
expression pattern of the above miRNAs in the tissues (Figure 6) was generally 
consistent with that of the HPV-positive cell lines. Importantly, miR-218 was found to be 
underexpressed (>2-fold reduction) in all the CIN III and CaCx samples compared to the 
normal cervix (Figure 6). On average, the CIN III samples showed a more limited  
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Figure 6. Expression of miRNAs and the SLIT2 gene in cervical tissues. qRT-PCR 
analysis of three cervical intraepithelial neoplasias type III (CIN III) and five cervical 
carcinomas (CaCx).  The normal cervix sample was obtained from Stratagene. G3PDH 
served as the endogenous control for SLIT2. 
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underexpression of miR-218 compared to the CaCx tissues. Since miR-218 is encoded 
by an intron of the SLIT2 tumor suppressor gene (Griffiths-Jones et al., 2006), we tested 
whether their expression is correlated. Previous analysis of global gene expression 
preformed in our lab via Human Genome U133A 2.0 Arrays (Affymetrix) also showed 
that SLIT2 was underexpressed in the HPV-positive cell lines. The qRT-PCR results 
showed that SLIT2 expression paralleled that of miR-218, and both of these were 
underexpressed in the CIN III and CaCx tissues (Figure 6). MiRNAs 143, 145 and 497 
that were underexpressed in the HPV-16 positive cell lines were also underexpressed in 
the HPV-positive tissues compared to the normal cervical tissue (Figure 6), although the 
relative levels of various miRNAs varied between the individual samples. In the case of 
miR-368, 5 out of 8 cervical cancer and CINIII lesions showed downregulation as 
compared to the normal cervix (Figure 6). Overall, the results obtained with the tissues 
provide further validation of the data obtained with the cervical cell lines. 
 
HPV-16 E6 oncogene downregulates miR-218 
 
To test whether E6 and/or E7 expression is directly correlated with reduced 
expression of miR-218, we utilized the osteosarcoma cell line U2OS either expressing 
the HPV-16 E6 or E7 gene, or the control neomycin resistance gene. The qRT-PCR 
results showed that both miR-218 and SLIT2 were underexpressed in the U2OS-E6 cell 
line compared to U2OS-E7 and the control U2OS-Neo cell line (Figure 7A). In another 
approach, the 20861 cell line containing integrated HPV-16 was transfected with HPV-
16 E6/E7 siRNAs. Since E6 and E7 are derived from alternative splicing of the same  
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Figure 7. HPV-16 E6 oncogene reduces the expression of miR-218. (A) qRT-PCR 
analysis of miR-218 and SLIT2 in U2OS-NEO, U2OS-16E6, and U2OS-16E7. (B) 
Expression of HPV-16 E6 and E7, miR-218 and SLIT2 in the 20861 cell line with or 
without RNAi against HPV-16 E6/E7. (C) qRT-PCR analysis of miR-218 in NOK-NEO, 
NOK cell line expressing the E6 gene of either the low-risk HPV-6 (NOK-6E6) or high-
risk HPV-16 (NOK-16E6). RNU43 served as the endogenous control for miRNAs, while 
G3PDH served as the endogenous control for E6, E7 and SLIT2. 
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RNA, a specific siRNA for E6 alone could not be used. The E6/E7 siRNAs reduced 
expression of these genes while increasing the expression of both miR-218 and the 
SLIT2 gene in 20861 cells (Figure 7B). These results indicate that the HPV-16 E6 gene 
is involved in the downregulation of miR-218 and the SLIT2 gene in HPV-16 positive cell 
lines. Since a U2OS derivative expressing the E6 gene of a low-risk HPV is not 
available, we utilized normal oral keratinocytes (NOK) expressing the HPV-6 E6 gene to 
study whether the E6 gene of a low-risk HPV also affects miR-218 expression. The 
qRT-PCR analysis showed that NOK-16E6 cells had reduced expression of miR-218 
compared to both NOK-NEO and NOK-6E6 (Figure 7C). These results suggest that the 
E6 gene of the high-risk HPV-16, but not the low-risk HPV-6, reduces miR-218 
expression. 
 
Laminin 5 β3 is a transcriptional target of miR-218 
 
To identify possible miR-218 targets, we compared computationally predicted 
targets in the miRBase Registry (Griffiths-Jones et al., 2006) with our gene expression 
data (manuscript in preparation), and then used the program rna22 
(http://cbcsrv.watson.ibm.com/rna22.html). This analysis revealed six possible targets of 
miR-218: emopamil binding protein (EBP), mitochondrial ribosomal protein S27 
(MRPS27), nucleoporin 93kDa (NUP93), ephrin-A1 (EFNA1), laminin 5 β3 (LAMB3) and 
muscleblind-like 2 (MBNL2). The expression of these genes was analyzed by qRTPCR 
in SiHa and 20861 cell lines transfected with an artificial miR-218 precursor molecule. 
After confirming the expression of mature miR-218 (Figure 8A), we found that  
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Figure 8. Expression of LAMB3 is reduced in the presence of miR-218. (A) Northern blot 
analysis of miR-218 after transfection of a precursor of miR-218 in SiHa and 20861 cell 
lines. U6 RNA was used as a loading control. (B) qRT-PCR analysis of LAMB3 in SiHa 
and 20861 cell lines transfected with a pre-miR-218. (C) Western blot analysis of 
LAMB3 protein in SiHa cells transfected with pre-miR-218. Location of the 40-kDa 
LAMB3 protein is indicated. G3PDH was used as a control. (D) Expression of LAMB3 
mRNA in the 20861 cell line with or without RNAi against HPV-16 E6/E7, and in the 
U2OS-NEO and U2OS-16E6 cell lines. G3PDH served as the endogenous control for 
LAMB3. 
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only the LAMB3 transcript was significantly underexpressed in miR-218 expressing cells 
(Figure 8B and data not shown). Furthermore, Western blot analysis showed that miR- 
218 expression also greatly reduced the levels of the LAMB3 protein in SiHa cells 
(Figure 8C). We also found that LAMB3 was underexpressed in the 20861 cell line in 
the presence of the E6/7 siRNAs compared to a control oligo (Figure 8D). Furthermore, 
U2OS-16E6 cells showed an increase in the levels of LAMB3 mRNA as compared to 
the U2OS-NEO cells (Figure 8D). Taken together, these results demonstrate that miR-
218 reduces LAMB3 expression at the transcriptional level. 
2.4 DISCUSSION 
The microarray data showed that 24 miRNAs were underexpressed and 3 
overexpressed in integrated HPV-16 cell lines compared to the normal cervix (Table 1). 
We also validated these data by Northern blot and qRT-PCR analyses of five miRNAs 
that were underexpressed (miR-143, miR-145, miR-218, miR-368 and miR-497) and 
three that were overexpressed (miR-193b, miR-200c and miR-205) in the HPV-16 
positive cell lines compared to the normal cervix or the HPV-negative cervical 
carcinoma cell line C-33A (Figure 5). The probable targets of the above eight miRNAs 
are shown in Supplementary Table 7. The observed differences in the levels of 
differentially expressed miRNAs were generally much greater in qRT-PCR and Northern 
blot studies as compared to the array data. Thus, the array data likely underestimate the 
fold-changes in the levels of differentially expressed miRNAs. Our studies identified 10 
underexpressed miRNAs in integrated HPV-16 cell lines that are not known to be 
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altered in any cancers. These included 7 known human miRNAs, miR-1, miR-126-AS, 
miR-133a, miR-376a, miR-451, miR-487b, miR-495, and 3 predicted miRNAs, ambi-
miR-5021, ambi-miR- 7029, and ambi-miR-7070. MiR-143 and miR-145, which are 
underexpressed in colon and breast cancers (Calin and Croce, 2006a), were also 
underexpressed in all cervical cell lines including C-33A (Tables 1 and 3), suggesting 
that they may be important in cervical carcinogenesis independent of HPV infection. 
MiR-368, miR-497 and miR-193b which are underexpressed in integrated HPV-16 cell 
lines are known to be underexpressed in colon cancer cell lines (Bandres et al., 2006), 
papillary thyroid carcinomas (Calin and Croce, 2006a), and colon cancer (Cummins et 
al., 2006), respectively. Interestingly, miR-218 was the only miRNA found to be 
underexpressed in integrated HPV-16 cell lines compared to both the normal cervix and 
C-33A cells (Tables 1 and 2, and Figure 5). Northern blot and qRT-PCR analysis 
showed that miR-218 is also underexpressed in HeLa cells containing integrated HPV-
18 DNA and the 20863 cell line containing episomal HPV-16 DNA (Figure 5, and 
Supplementary Figure 1). These results suggest that miR-218 may be a specific cellular 
target of high-risk HPVs. MiR-218 is known to be underexpressed in several cancers 
and the DNA encoding miR-218 is also deleted in ovarian, breast, and melanoma 
cancers (Calin and Croce, 2006a) (Zhang et al., 2006). Of the miRNAs overexpressed 
in integrated HPV-16 cell lines, miR-210 is overexpressed in many epithelial cancers 
(Calin and Croce, 2006a), while miR-182 and miR-183 are overexpressed in colon 
cancer cell lines (Bandres et al., 2006). We also found that 6 miRNAs have reduced 
expression in the episomal HPV-16 cell line 20863 compared to the normal cervix 
(Supplementary Table 2). These miRNAs may represent early targets of HPV-16 
 37 
infection. A comparison of the miRNA expression profile of HPV-16 and HPV-18 
positive cell lines with that of the normal cervix showed that while some miRNAs are 
similarly affected in the HPV-16 and HPV-18 positive cells, others are not. This may 
indicate the presence of both common as well as unique pathways that are altered in 
cells containing HPV-16 and HPV-18 DNA.  
Analysis of 6 representative miRNAs, miR-143, miR-145, miR-200c, miR-218, 
miR-368 and miR-497 (whose expression levels in various cell lines were also analyzed 
by a variety of methods) in CIN III and CaCx tissues by qRT-PCR showed expression 
patterns that were generally similar to those of the HPV-positive cell lines (Figures 5 
and 6). Importantly, miR-218 was also underexpressed (>2-fold difference) in all the CIN 
III and CaCx tissues (Figure 6). These results suggest that miR-218 underexpression is 
likely linked to the process of HPV-associated carcinogenesis in vivo. The parallel 
expression of miR-218 and the SLIT2 gene (which encodes miR-218) in all the tumor 
tissues (Figure 6) suggests that they may be coordinately regulated. Previous studies 
have shown that the SLIT2 tumor suppressor gene is frequently inactivated in lung and 
breast cancers (which have reduced miR-218 levels) (Dallol et al., 2002). Whether 
regulation of SLIT2 plays a role in the pathogenesis of HPV-associated malignancies is 
currently unknown. 
Our results showed that both miR-218 and SLIT2 were underexpressed in the 
U2OS-16E6 cell line (Figure 7A). Similarly, miR-218 was also underexpressed in NOK- 
16E6 but not in the NOK-6E6 cell line (Figure 7C). These results suggest that E6 of the 
high-risk HPV-16, but not the low-risk HPV-6, may contribute to the downregulation of 
miR-218. This possibility is also supported by our observations that expression of E6/E7 
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siRNAs in 20861 cells increases miR-218 and SLIT2 mRNA levels (Figure 7B). 
Interestingly, SLIT2 is a possible target of miR-200c (overexpressed in the HPV-positive 
cell lines and tissues) (Supplementary Table 7). One study has shown that the absence 
of the p53 gene increases miR-200c expression (Xi et al., 2006). Thus, it is possible that 
E6-dependent degradation of the p53 protein results in miR-200c overexpression which 
in turn reduces the levels of miR-218 and SLIT2 mRNA. 
Our studies showed that introduction of miR-218 into SiHa and 20861 cell lines 
reduced the levels of Laminin 5 β3 (LAMB3) mRNA as well as the protein (Figure 8A, B, 
C). This strongly supports implies that miR-218 can downregulate LAMB3 expression 
independent of SLIT2. Furthermore, introduction of E6/E7 siRNA into the 20861 cell line 
also reduced LAMB3 expression (Figure 8D). Also, E6 expression in U2OS cells 
increased LAMB3 expression (Figure 8D) presumably by reducing miR-218 expression. 
Taken together, the above studies suggest that miR-218 may regulate LAMB3 
expression at the transcriptional level. LAMB3 protein is part of the polymeric cell 
surface receptor laminin 5 that is expressed in the basal lamina of the epithelium and is 
overexpressed in cervical cancers (Skyldberg et al., 1999) (Kohlberger et al., 2003). 
LAMB3 increases cell migration and tumorigenicity in SCID mice, and in collaboration 
with its ligand α6β4-integrin promotes tumorigenesis in human keratinocytes (Dajee et 
al., 2003) (Calaluce et al., 2004). A recent study suggests that secreted laminin 5 can 
be used by HPV as a transient receptor to aid the virus in the infection of basal cells that 
express α6β4-integrin (Culp et al., 2006). Thus, downregulation of miR-218 by E6 and 
the consequent overexpression of LAMB3 may promote viral infection of the 
surrounding tissue and contribute to eventual tumorigenesis. 
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3.0  CHAPTER 3 
MICRORNA ANALYSIS IN HUMAN PAPILLOMAVIRUS (HPV)-ASSOCIATED 
CERVICAL NEOPLASIA AND CANCER 
 
Work described in this section has been submitted for publication. The authors are Amy 
S. Gardiner, William C. McBee, Jr., Robert P. Edwards, Jamie L. Lesnock, Rohit 
Bhargava, R. Marshall Austin, Richard S. Guido, and Saleem A. Khan. Amy S. 
Gardiner and William C. McBee Jr. contributed equally to this work. 
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3.1 INTRODUCTION 
Worldwide, cervical cancer is the most common gynecologic malignancy.  The 
estimated incidence in 2002 was 493,243 new cases and an associated 273,505 related 
deaths, making it the third most deadly cancer, behind breast and lung cancers (Parkin 
et al., 2005).  Cervical cancer is a major health concern in the United States as well.  In 
2008 there were an estimated 11,070 new cases and an associated 3,870 deaths, 
accounting for approximately 1% of cancer deaths in women. Developed countries such 
as the United States have seen a significant decrease in the incidence of invasive 
cervical cancer during the past 50 years.  This is largely due to the widespread use of 
effective screening techniques.  However, the incidence of invasive cervical cancer still 
remains disproportionately higher in minorities and others with limited access to 
healthcare.  
Due in large part to increased screening for cervical cancer, the incidence of 
patients diagnosed with cervical dysplasia has increased exponentially over the past 50 
years. Currently, it is estimated that between 250,000 and 1,000,000 women in the 
United States will be diagnosed with cervical intraepithelial neoplasia (CIN) annually.  
The stepwise progression of mild to moderate to severe dysplasia, and eventually to 
invasive cervical cancer has been well documented.  The management of patients with 
cervical dysplasia should be focused on the prevention of invasive cervical cancer.  
There is a huge expenditure required to diagnose, follow, and treat patients with cervical 
dysplasia, in order to prevent the development of invasive cancer. 
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Human papillomaviruses (HPVs) are the causative agents in essentially all 
cervical dysplasia and invasive cervical cancer (Walboomers et al., 1999). There are 
more than 100 documented HPV types, and approximately forty have the propensity to 
cause malignant changes, in varying degrees, in the anogenital epithelium (de Villiers et 
al., 2004). HPV infection is extremely common in sexually active individuals, with some 
reported lifetime incidence rates as high as 80% in women by the age of 50 (Ho et al., 
1998).  While the overall lifetime incidence of HPV infection in women is high, the virus 
is usually transient and the majority of infections are cleared in less than a year (Ho et 
al., 1998). Nevertheless, some patients are found to have cervical dysplasia that is often 
persistent and often more virulent.  The ability to identify which cervical HPV infections 
will become cancers would markedly reduce our resource utilization currently required 
to prevent cervix cancer.  Such a reduction would presumably make cervical cancer 
prevention more affordable to the third world where it remains a significant problem.  
HPVs are small, circular, non-enveloped, double stranded DNA viruses, about 8000 
base pairs in size (zur Hausen, 2002).  Early in HPV infection, the non-structural genes 
E1, E2, E4, E5, E6, and E7 are expressed.  Later in the viral life cycle, the late structural 
genes L1 and L2 are expressed. This coincides with a burst of viral replication and 
transcription; virions are shed which infect surrounding tissue (Lee and Laimins, 2004).  
The E6 and E7 oncogenes work synergistically to deregulate cell cycle controls through 
a variety of mechanisms. The E6 oncogene promotes ubiquitination and proteasomal 
degradation of the tumor suppressor protein p53 and also deregulates the cell cycle 
(Scheffner et al., 1990) (Thomas et al., 1999) (Werness et al., 1990). The E7 protein 
binds to and inactivates the function of pRB and the related tumor suppressor proteins 
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p107 and p130 (Davies et al., 1993).  Expression of E6 and E7 promotes chromosomal 
instability, foreign DNA integration, and other mutagenic events in the cell (Duensing et 
al., 2000) (Pett et al., 2004). This chromosomal instability is a hallmark of cancer.   
 MicroRNAs (miRNA) are small, non-coding RNAs (approximately 22 nucleotides 
in length) that regulate gene expression (Ambros, 2003).  MicroRNAs function by 
binding to the 3’ UTRs of their target messenger RNA (mRNA), whereby they induce 
mRNA degradation or repression of translation (Farh et al., 2005). The functions of 
miRNAs are still largely unknown but they appear to be integral to modulation of gene 
expression and cell behavior.  Recent studies have suggested that they may play a role 
in the development of a variety of cancers (Calin and Croce, 2006a). Differentially 
expressed miRNAs may serve as early biomarkers for the progression of cervical 
dysplasia.  Furthermore, the development of a biomarker panel may be useful for 
determining which patients with cervical dysplasia are likely to have disease 
progression and may also be a useful prognostic indicator in patients with invasive 
cancer.  We compared the miRNA expression profiles in cervical cancer, dysplasia and 
normal cervix, and we report the identification of several miRNAs whose dysregulation 
is associated with the progression of HPV induced disease from mild dysplasia to 
invasive cancer. 
3.2 MATERIALS AND METHODS 
Cervical Tissue Collection and Characterization 
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After IRB approval had been obtained, prospective collection of cervical tissue 
was performed from various grades of neoplasia.  Patients with preinvasive and grossly 
invasive cervical lesions undergoing excision were recruited for adjacent biopsies of the 
cervical lesion.  One biopsy was snap frozen for our analysis and the other was sent to 
pathology for tissue diagnosis.  Patients with microinvasive disease or prior radiation 
were excluded. 
Cervical dysplasia specimens were collected from patients at the time of 
colposcopy and excision using a similar paradigm of adjacent biopsy techniques.  After 
the LEEP excision was performed, a small sample from the area of suspected dysplasia 
was removed for miRNA analysis.  The LEEP specimen was then sent for pathologic 
review. In addition to the standard pathologic review, the gynecologic pathologist 
evaluated the cervical tissue directly adjacent to the tissue that was removed for 
analysis.  We used this analysis to grade the level of dysplasia in our sample.  We only 
analyzed CIN 2 and 3 lesions.  Any tissue collected with mild, or no dysplasia, was not 
processed.   
Normal cervical tissue was also collected from controls, age-matched to the 
cervical cancer patients. This tissue was obtained from the Magee-Womens tissue bank 
(from a separate IRB) for patients with normal cervical cytology who had undergone a 
hysterectomy for a benign indication. Normal cervical samples were obtained from the 
transformation zone, to correspond to that taken from the dysplasia and cancer patients. 
All cervical tissue was directly evaluated by a gynecologic pathologist. 
Once tissue was collected, it was snap frozen and stored at -80°C for later use.  
Next, a piece of the tissue was removed for DNA isolation and another for RNA 
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isolation.  After DNA isolation, tissue samples were confirmed to be either HPV-positive 
or HPV-negative by PCR analysis using the MY09/MY11 primer set for amplification of 
the highly conserved HPV L1 structural gene (Manos et al., 1994). Amplification of the 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used as a control, 
using the forward primer 5′-ACCACAGTCCATGCCATCAC-3′ and reverse primer 5′-
TCCACCACCCTGTTGCTGTA-3′. HPV-positive samples were then tested for the 
presence of HPV type 16 or 18 by PCR analysis of their respective E6 oncogene. The 
primers used were 5′-ATGCACCAAAAGAGAACTGC -3’ (forward) and 5’-
TTACAGCTGGGTTTCTCTAC-3’ (reverse) for HPV-16 E6 and 5’-
CGGCGACCCTACAAGCTACCTG-3’ (forward) and 5’-
CTGCGTCGTTGGAGTCGTTCC-3’ (reverse) for HPV-18 E6. The majority of the 
tissues were HPV-16 positive, and we proceeded with the analysis of only such 
samples (dysplasia or cancer). The HPV-negative normal cervical tissues were also 
confirmed to have completely benign pathology.   
Total RNA was isolated from all the cervical tissues using the Ultraspec™ RNA 
Isolation System (Biotecx, Houston, TX, USA) and analyzed by agarose gel 
electrophoresis.  The HPV E6 and E7 oncogenes have been shown to be required for 
cellular transformation and directly responsible for cervical disease progression.  
Therefore, DNase-I-treated total RNA (1 µg) from HPV-16 positive tissues was 
subjected to RT-PCR analysis for the expression of the E6 and E7 oncogenes using the 
forward primer 5′-GTAACCTTTTGTTGCAAGTGTGACT-3′ and the reverse primer 5′-
GATTATGGTTTCTGAGAACAGATGG-3′, and the Advantage® Clontech RT-for-PCR 
Kit (Clontech, Mountain View, CA, USA) according to the manufacturer’s instructions.  
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MicroRNA Real-time Quantitative RT-PCR Analysis 
 
We carried out miRNA expression analysis using the TaqMan® MicroRNA Reverse 
Transcription Kit and Megaplex™ RT Primers, followed by TaqMan® Human MicroRNA 
Arrays V2.0 from Applied Biosystems, which are designed for the sensitive amplification 
and profiling of 667 unique human miRNAs.  The arrays also contain primers for three 
endogenous small RNAs U6, RNU44, and RNU48, which serve as positive controls, as 
well as primers for an A. thaliana miRNA, which serves as a negative control.  This 
approach is based on real-time quantitative PCR and we used 1.5 µg of total RNA per 
sample for miRNA expression analysis.  Amplification of all miRNAs was carried out 
according to the manufacturer’s instructions and the samples were analyzed on the 
7900HT Fast Real-Time PCR System (Applied Biosystems).  The relative quantification 
of miRNAs was performed using the 2 delta Ct method, where change in expression of 
a gene in an experimental sample is quantified relative to the same gene in a reference 
sample.  We used two-fold as the cut-off ratio for identification of differentially expressed 
miRNAs.  Data analysis was performed first by comparing cervical cancer tissue to 
normal cervical tissue for all overexpressed and underexpressed miRNAs, using a 
statistical significance level of p=0.05.   
MiRNAs found to be overexpressed or underexpressed in the cancer or 
dysplasia samples as compared to the normal cervical tissue were further analyzed by 
individual quantitative RT-PCR (qRT-PCR) analysis using the TaqMan® MicroRNA 
Reverse Transcription Kit and individual TaqMan® MicroRNA Assays (Applied 
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Biosystems) according to the manufacturer’s instructions.  The RNA used in these 
experiments was normalized to the small nucleolar (Winn et al.) RNU43 levels and 
relative expression levels of miRNAs were calculated using the 2 delta CT method. 
3.3 RESULTS 
Patients were identified for tissue collection from March 2008 until May 2009.  
We collected and analyzed 4 patients with normal cervical tissue, 3 with cervical 
dysplasia, and 6 with cervical cancer.  We only analyzed dysplasia samples in patients 
with pathologically confirmed CIN 2 or CIN 3 lesions.  For patients with cervical cancer, 
we only analyzed patients with squamous cell carcinoma.   
Patient characteristics, including pathology and treatment information, are shown 
in Table 3.  Due to the small sample size, we included only those patients with cervical 
cancer or dysplasia that were found to be HPV 16 positive by PCR analysis (not 
shown).  Based on the results of the qRT-PCR analysis, all HPV-16 samples were also 
found to express the E6 and E7 oncogenes (data not shown).   
Based on the TaqMan® MicroRNA Array data from the cervical tissue samples, 
we found that 20 miRNAs were differentially expressed in cervical cancer compared to 
the normal cervical tissue at p<0.05.  Of these, eighteen miRNAs were overexpressed 
and two were underexpressed.  The fold change of various miRNAs ranged from 2.8 to 
58.2. (Table 4)  Unsupervised hierarchical clustering grouped the samples into two 
categories based on their miRNA expression, with the dysplasia samples grouping more  
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Table 3. Patient Characteristics 
Sample Specimen 
Number 
Type Patient 
Age 
Diagnosis Stage Treatment 
1 
 
32 Benign 51 Uterine 
Prolapse 
n/a Hysterectomy 
2 49 Benign 39 H/O Breast 
Cancer 
n/a Hysterectomy 
3 
 
167 Benign 35 Menorrhagia n/a Hysterectomy 
4 
 
367 Benign 50 Menorrhagia n/a Hysterectomy 
5 
 
79 Dysplasia 56 CIN 3 n/a LEEP 
6 
 
80 Dysplasia 27 CIN 2 n/a LEEP 
7 
 
83 Dysplasia 26 CIN 2 n/a LEEP 
8 33 Cancer 71 Squamous 
Cell 
Carcinoma 
3B XRT/Chemo 
9 42 Cancer 40 Squamous 
Cell 
Carcinoma 
2B XRT/Chemo 
10 47 Cancer 52 Squamous 
Cell 
Carcinoma 
3B XRT/Chemo 
11 52 Cancer 61 Squamous 
Cell 
Carcinoma 
1B1 Radical 
Hysterectomy 
12 57 Cancer 38 Squamous 
Cell 
Carcinoma 
1B2 Radical 
Hysterectomy 
13 81 Cancer 34 Squamous 
Cell 
Carcinoma 
1B1 Radical 
Hysterectomy 
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Table 4. MiRNAs differentially expressed in cervical cancer tissue compared to normal 
cervical tissue (p<0.05).   
MiRNA Fold change 
Overexpressed   
hsa_miR_124 58.2 
hsa_miR_449a 35.3 
hsa_miR_449b 30.5 
hsa-miR- 301b 24.3  
hsa_miR_517c 22.4 
hsa_miR_545 17.4 
hsa_miR_223 14.2 
hsa_miR_135b 11.1 
hsa_miR_21 9.6 
hsa_miR_512_3p 9.4 
hsa_miR_542_3p 7.8 
hsa_miR_181c 7.6 
hsa_miR_517a 6.9 
hsa_miR_518f 5.0 
hsa_miR_106b 4.3 
hsa_miR_192 3.8 
hsa_miR_16 3.8 
hsa_miR_141 2.8 
Underexpressed   
hsa_miR_433 -18.6 
hsa_miR_218 -5.6 
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closely with the normal cervical tissue than the cervical cancer tissue (Figure 5).  The 18 
miRNAs on the top are overexpressed in cervical cancer compared to the normal  
cervical tissue.  Two miRNAs, shown at the bottom (miR-433 and miR-218), are 
underexpressed in cervical cancer compared to the normal cervical tissue.  The 3 
dysplasia samples (CIN79, CIN80, and CIN83) show differential expression of the 
twenty miRNAs (Figure 9).   
To validate the miRNA data obtained from array analysis, we carried out 
individual qRT-PCR analysis of the 20 differentially expressed miRNAs.  We identified 
10 miRNAs that most significantly differed in the cancer tissues compared to the normal 
cervical tissues.  The individual qRT-PCR expression plots for these differentially 
expressed miRNAs, showing relative quantification for each sample, are shown in 
Figure 10. We found that several miRNAs were generally overexpressed in cancer 
specimens compared to both normal and dysplasia tissue.  This included miR-135b, 
miR-223, and miR-301b.  A number of miRNAs such as miR-16, miR-21, miR-106b, 
miR-141, and miR-449a were generally overexpressed in both cancer and dysplasia 
specimens compared to the normal cervical tissue. MiR-218 and miR-433 were mostly 
underexpressed in the cancer and dysplasia tissues compared to the normal cervical 
samples. For many of the miRNAs such as miR-16, miR-21, miR-106b, miR-141, miR-
449a (overexpressed) miR-218, and miR-433 (underexpressed), the dysplasia samples 
showed mixed results.  Some of the dysplasia specimens such as CIN83, appeared 
more similar to the normal cervical tissue samples, while others such as CIN79 and 
CIN80, were more similar to the cancer tissue samples (Figure 10).    
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Figure 9. Unsupervised hierarchical clustering  (p<0.05) of cellular miRNAs with 
increased (Ang et al.) or decreased expression (green) in cervical cancer tissue, 
cervical dysplasia, and normal cervical tissue, based on TaqMan® MicroRNA Array 
data. 
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Figure 10. Individual qRT-PCR expression plots for miRNAs differentially expressed in 
normal cervical tissue, cervical dysplasia, and cervical cancer tissue. 
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We next sought to identify potential gene targets of the miRNAs we found differentially 
expressed in our tissue samples. We evaluated gene expression signatures reported by 
Gius et al. 2007, in which they utilized National Cancer Institute ROSP 8K human arrays 
to identify differentially expressed genes from the normal cervix, cervical dysplasias, 
and cervical squamous cell carcinomas from both epithelial and underlying stromal 
tissues (Gius et al., 2007). We compared this data with bioinformatically predicted gene 
targets from MicroCosm Targets for the miRNAs in our study. Table 5 displays potential 
gene targets for the ten miRNAs found to be most significantly over or under expressed 
in our analysis. 
3.4 DISCUSSION 
Changes in miRNA expression have been linked to many cancers.  They are 
often found near fragile sites in chromosomes or near integration sites of high risk HPVs 
(Lee et al., 2002).  MicroRNAs can either serve as tumor suppressor genes or 
oncogenes.  Over expression of miRNAs that target oncogenes can lead to increased 
destruction of these oncogenes and therefore tumor suppression. Conversely, over 
expression of miRNAs that target tumor suppressors can result in increased oncogenic 
activity and tumor formation.  MicroRNAs have been found to regulate the oncogenes 
Bcl and Ras as well as the tumor suppressor pRb (Volinia et al., 2006). MiR-15 and 
miR-16 were the first miRNAs shown to be associated with cancer; they were found to 
be down regulated in chronic lymphocytic leukemia (CLL) (Calin et al., 2002).  
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Table 5. Potential gene targets of miRNAs differentially expressed in cervical dysplasia 
and cancer. Computational targets of miRNAs differentially expressed in our study were 
obtained from MicroCosm and cross-referenced with genes that were also found to be 
differentially expressed in cervical dysplasia and cancer (Gius et al., 2007). Genes 
underexpressed in cervical dysplasia and cancer are potential targets of miRNAs that 
are overexpressed, and similarly, genes overexpressed in cervical dysplasia and cancer 
are potential targets of miRNAs that are underexpressed. 
MiRNA Potential Targets 
Overexpressed Underexpressed 
miR-16 
CDA, CDC37, NPC1, PPL, PVRL2, TGM1, ACAA1, PPAP2A, RBX1, 
UCP2, WNT7A 
miR-21 
ANXA1, CD48, DNAJA2, EIF4G2, EPHX1, IL13RA1, C2, DDAH1, 
PLA2G4A 
miR-106b DPAGT1, NINJ2, TBX19, ATP5F, FUT3, TPT1 
miR-135b 
ACAA1, DDX58, IL13RA1, SPINK5, AREG, HNRPA1, HNRPAB, 
NDUFA6 
miR-141 EPHA2, NPC1, BRWD1, DR1, SELE 
miR-223 DSG3, EIF4G2, BAG1, RBBP6 
miR-301b PPL, RASAL1, TBX1, TERF2, TGM1, C2, H19, RPS10, SELE 
miR-449a CDA, CDC37, NPC1, PPL, PVRL2, TGM1, AREG, ARHGBIB 
Underexpressed Overexpressed 
miR-218 C1ORF41, RTCD1, SHMT2, SSR1, BAI3, CCNI, EBI2, HAS3, IGF2, 
MMP3, MTIG, PLAUR, PRIM2A, PSMB7, RGS1, RPS29 
miR-433 GPR56, MRPL33, PABPC4, TARBP1, C1S, CD1A, CUL2, ISGF3G, 
NM1, RPS16, TRIP12 
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Figure 11. miR-218 reduces the expression of MMP3. (A) Binding site for miR-218 in 
the 3’UTR of MMP3. (B) qRT-PCR expression for MMP3 in SiHa cells transfected with a 
negative control precursor miRNA molecule or pre-miR-218. Standard deviation was 
calculated from three replicates (p<0.05). 
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MicroRNAs have been shown to negatively regulate the Bcl-2 oncogene that is 
over expressed in many cancers (Cimmino et al., 2005). The let-7 family of miRNAs 
regulates the ras oncogenes, which contain activating mutations in about 15-30% of 
cancers (Johnson et al., 2005).  Downregulation of the let-7 family of miRNAs results in 
the upregulation of ras, which is most pronounced in lung cancers (Takamizawa et al., 
2004). 
In the current study, we have demonstrated significant overexpression of 18 
miRNAs and underexpression of two miRNAs.  Similar to other work performed in the 
field, we specifically showed overexpression of miR-16 and miR-21, and 
underexpression of miR-218 in the cervical cancer tissues compared to normal cervical 
tissues (Martinez et al., 2008) (Lee et al., 2008). In addition to showing differential 
expression of miRNAs in cervical cancer tissue, this is one of the first published reports 
of differential expression of miRNAs in cervical dysplasia.  We showed overexpression 
of miR-16, miR-21, miR-106b, miR-141, and miR-449a, and underexpression of miR-
218 and miR-433. This differential expression was seen in the moderate/severe 
dysplasia samples as compared to the normal cervical samples.  Other miRNAs 
showed similar expression patterns in dysplasia and normal cervix, such as miR-135b, 
miR-223, and miR-301b, which were generally overexpressed in cervical cancer 
samples.     
Wang et al. identified several miRNAs via microarray that were deregulated in 
cervical cancer tissue (Wang et al., 2008).  They found miR-15b, miR-16, miR-146a, 
and miR-155 to be highly overexpressed in cervical cancer tissues and miR-126, miR-
143, and miR-145 to be underexpressed.  In common with our study, they found that 
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miR-16, miR-21, miR-181c, and miR-223 were overexpressed and miR-218 was 
underexpressed (Wang et al., 2008). Using a cloning strategy to identify differentially 
expressed miRNAs, Lui et al. analyzed the respective cloning frequency of miRNAs in 
cervical carcinoma cell lines versus normal cervical tissue (Lui et al., 2007).  They 
further evaluated the expression levels of miR-21 and miR-143 and found significant 
overexpression of miR-21 and underexpression miR-143 in cervical cancer cell lines 
and tissues versus normal cervical tissue (Lui et al., 2007). In previous research 
performed in our laboratory, Martinez et al. showed that miR-218 was significantly 
underexpressed in HPV-16 positive cervical cancer cell lines and tissues (Martinez et 
al., 2008). 
Lee et al. analyzed 157 cellular miRNAs via the TaqMan® MicroRNA Human 
Early Panel Kit (Applied Biosystems) in 10 cervical cancer specimens and 10 normal 
cervical specimens.  They found overexpression of 68 miRNAs and underexpression of 
two.  They found that the 10 miRNAs that were most overexpressed were miR-199-s, 
miR-9, mir-199*, miR-199a, miR-199b, miR-145, miR-133a, miR-133b, miR-214, and 
miR-127.  Only 2 miRNAs (miR-149 and miR-203) were found underexpressed.  In 
common with our study, they found that miR-16, miR-21, miR-135b, and miR-181c were 
overexpressed.  Of note, the cervical cancer tissues were not characterized by HPV 
type (Lee et al., 2008). Taken together, the miRNA expression patterns in cervical 
cancer that appear to be common in our study and those of others, are overexpression 
of miR-16 and miR-21 and underexpression of miR-218. 
Many of the differentially expressed miRNAs from our study are differentially 
expressed in a variety of other cancers as well.  MiR-16 is overexpressed in serous 
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ovarian cancer (Nam et al., 2008) as well as cancer of the head and neck (Hui et al.).  
Several researchers have shown overexpression of miR-21 in the following cancers: 
ovarian (Lui et al., 2007), head and neck (Hui et al.), lung (Zhang et al., 2010), stomach 
(Guo et al., 2008), liver (Jiang et al., 2008), and pancreas (Lee et al., 2007).  
Overexpression of miR-106b has been demonstrated in gastric (Guo et al., 2008) and 
colorectal cancer (Wang et al., 2010b), as well as squamous cell carcinoma of the head 
and neck (Hui et al.).  MiR-135b was found overexpressed in colorectal (Wang et al., 
2010b) (Bandres et al., 2006) (Sarver et al., 2009) and prostate (Tong et al., 2009) 
cancer.  Nam et al. showed that overexpression of mir-141 was associated with a poor 
prognosis in patients with serous ovarian carcinoma (Nam et al., 2008). MiR-223 was 
shown to be overexpressed in adult T-cell leukemia (Bellon et al., 2009) and 
adenocarcinomas of the esophagus (Mathe et al., 2009).  Conversely, miR-218 is 
underexpressed in a variety of cancers including breast, ovarian, and melanomas 
(Volinia et al., 2006) (Zhang et al., 2006). Lastly, Ueda et al. and Luo et al., in separate 
studies, showed underexpression of miR-433 in gastric cancer (Ueda et al., 2010) (Luo 
et al., 2009). 
The regulation of various gene targets by miRNAs has also been studied.  
Relevant to our study, Kaddar et al. demonstrated that miR-16 can negatively regulate 
genes that are involved in cell proliferation, such as HMGA1 and caprin-1 in MCF-7 and 
HeLa cells, but miR-16 induced G1 accumulation occurred only in MCF-7 cells, not in 
HeLa cells, which contain HPV-18 DNA integrated into the chromosome (Kaddar et al., 
2009). The authors speculate that this is most likely due to the status of p53 and Rb, 
which function normally in MCF-7 cells but are inactivated in HeLa cells. Lack of miR-16 
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induced G0/G1 accumulation in HeLa cells was also observed by another group (Bandi 
et al., 2009). MiR-21 was found to downregulate the tumor suppressor PTEN in non-
small cell lung cancer (Zhang et al., 2010), as well as in hepatocellular cancer (Meng et 
al., 2007).  MiR-21 also targets the tumor suppressor gene tropomyosin 1 (TPM1) (Zhu 
et al., 2007), and the tumor suppressor genes programmed cell death 4 (PDCD4) and 
maspin, both of which have been implicated in tumor invasion and metastasis (Zhu et 
al., 2008). MiR-218 targets the OC-2 transcription factor during liver and pancreatic 
development (Simion et al., 2010). A recent study demonstrated that in gastric cancer 
miR-218, which is encoded in Slit genes, can target Robo1, providing a negative 
feedback loop through the Robo-Slit interaction (Tie et al., 2010).  
We identified potential targets of miRNAs in cervical cancer (Table 5). Gene 
expression data from Gius et al. was cross-referenced with gene targets from 
MicroCosm Targets to identify a number of potential targets for the miRNAs in our study 
(Gius et al., 2007). WNT7A, a potential target for miR-16, is downregulated in cervical 
cancer (Gius et al., 2007) and has been shown to have an antitumorigenic effect in non-
small cell lung cancer (Winn et al., 2006). MiR-21 may target annexin A1 (ANXA1) and 
EIF4G2, which are downregulated in cervical cancer (Gius et al., 2007). Reduced 
expression of ANXA1 is associated with advanced stage breast cancer (Wang et al., 
2010a), and downregulation of EIF4G2 correlates with invasive transitional cell 
carcinoma of the bladder (Buim et al., 2005). Interestingly, matrix metalloproteinase 3 
(MMP3), which has been shown by several groups to be upregulated in cervical cancer 
(Gius et al., 2007) (Hagemann et al., 2007), is a potential target of miR-218 (Figure 11).   
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Identification of a panel of miRNAs that can be used as early biomarkers in 
cervical cancer is potentially useful to determine disease behavior and prognosis.  
Targets of miRNAs may also provide new targets for anti-cancer therapy.  The 
progression of invasive cervical cancer from mild, asymptomatic HPV infection to 
advanced stage invasive cervical cancer has been well documented.  Although the 
majority of patients with moderate cervical dysplasia, even if untreated, will not progress 
to cervical cancer, a significant fraction will.  MicroRNA expression profiling may enable 
us to identify those women with more aggressive disease and therefore provide more 
aggressive treatment for such patients. 
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4.0  CHAPTER 4 
HUMAN PAPILLOMAVIRUS (HPV)-16 E6 REGULATES MICRORNA-218 VIA THE 
HISTONE ACETYLTRANSFERASE P300 
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4.1 INTRODUCTION 
Human papillomaviruses are causative agents of cervical cancer (Walboomers et 
al., 1999). HPVs encode two oncogenes, E6 and E7, which serve to immortalize cells. 
E7 interacts with pRb family members (Chellappan et al., 1992), resulting in the 
expression of S phase genes but also activation of the p53 stress response (Moody and 
Laimins, 2010). E6 then targets p53 in complex with E6AP (Werness et al., 1990) 
(Huibregtse et al., 1991), resulting in p53 ubiquitination and degradation (Scheffner et 
al., 1990). E6 interacts with a number of other cellular proteins, including histone 
acetyltransferases p300/CBP (Patel et al., 1999) (Zimmermann et al., 1999). This 
interaction prevents acetylation of p53, further preventing p53-mediated transcription.  
MicroRNAs are ~22 nt single-stranded gene regulators, which most often 
function to repress translation or degrade mRNA transcripts (Kim, 2005). They are 
important in cellular development and differentiation, and deregulation of miRNAs has 
been reported for many cancers (Calin and Croce, 2006a). In cervical cells, miR-34a 
and miR-203 are targets of p53. MiR-34a regulates CDK4 and CCNE2, and directly 
targets E2F3 and SIRT1 (Vecchione and Croce, 2010). MiR-203 regulates p63 
(McKenna et al., 2010). We previously showed that miR-218 is underexpressed in HPV-
16 positive cervical carcinoma cells, and HPV-16 E6 specifically downregulates miR-
218 (Martinez et al., 2008). MiR-218 in turn targets LAMB3, a component of the 
basement membrane protein laminin5, which can serve as a transient receptor for HPV 
(Martinez et al., 2008). We also showed that miR-218 is underexpressed in HPV-16 
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positive cervical dysplasias and cancer (see Chapter 3). In this study, we sought to 
understand the mechanism of regulation of miR-218 by HPV-16 E6. We found that E6 
regulates miR-218 through the histone acetyltransferase p300, and this function is not 
dependent on p53. We also found that miR-218 reduces the migration and invasion of 
cervical carcinoma cells. 
4.2 MATERIALS AND METHODS 
Cell culture, transfections, and infections 
 
LXSN vectors encoding wild-type HPV-16 E6 and the E6 mutants L50G and 
G130V were obtained from Dr. Elliot Androphy (Indiana University). HEK293 cells were 
seeded 2x106 in 10 mm plates and transfected the next day with 5 µg ampho plasmid 
and 10 µg LXSN DNA. After 48-72 hrs, the viral supernatant was collected, filtered, and 
added to U2OS cells. Following an additional 48 hr, the cells were harvested and RNA 
extracted using the Trizol reagent (Invitrogen). Cervical cancer cell line SiHa (HPV-16 
positive) was seeded 1 x105 in 12-well plates and transfected the next day with 250 nM 
siRNA molecules targeting EZH2 (Dharmacon) using Lipofectamine 2000 (Invitrogen). 
The HPV-negative cervical cancer cell line C-33A was also seeded 1 x105 and 
transfected the next day with 250 nM siRNA molecules targeting p300 (Dharmacon) 
using Lipofectamine 2000 (Invitrogen). Fluorescent BLOCK-iT was used to check 
transfection efficiency (Invitrogen). After 48 hr, the cells were harvested and RNA 
extracted with Trizol (Invitrogen). 
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Drug treatments 
 
SiHa cells were seeded 1 x105 in 12-well plates and treated the next day with 
either DMSO, 5 µM 5-azacytidine, 0.5 µM trichostatin A, 50 µM adenosine dialdehyde, 
or a combination. C-33A cells were seeded 1 x105 in 12-well plates and treated the next 
day with either DMSO or 30 µM anacardic acid. 
 
MicroRNA and mRNA Real-Time Quantitative RT-PCR Analysis 
 
Total RNA (10 ng) was subjected to qRT-PCR analysis using the TaqMan® 
miRNA Reverse Transcription Kit and miRNA Assays (Applied Biosystems, USA), and 
the Real-Time thermocycler iQ5 (BioRad, USA). The small nucleolar RNU43 was used 
as the housekeeping small RNA reference gene for miR-218. For qRT-PCR analysis of 
SLIT2, SLIT3, p300, and EZH2 mRNAs, 300 ng of total RNA was amplified using the 
one-step QuantiTect SYBR Green RT-PCR Master Mix (Qiagen, USA). The following 
primers were used: (SLIT2, forward 5’-CTGTGAATGCAGCAGTGGAT-3’ and reverse 
5’-TTGTTTGGCAAGCAGCATAG-3’ (116-bp product); SLIT3 forward 5’-
GCGCCTGAACAAGAATAAGC-3’ and reverse 5’-GATCCCCTGGATCTGGTTTT-3’ 
(103-bp product; p300 forward 5’-TAAACTCTCATCTCCGGCCC-3’ and reverse 5’-
CCACCATTGGTTAGTCCCAA-3’ (129-bp product; EZH2 forward 5’-
GGAACAACGCGAGTCGG-3’ and reverse 5’-CTGATTTTACACGCTTCCGC-3’ (102-bp 
product). The primer sequences for the control housekeeping glyceraldehyde-3-
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phosphate dehydrogenase gene (G3PDH) have been described previously (Martinez et 
al., 2007). All reactions were done in triplicate and relative expression of RNAs was 
calculated using the 2 delta CT method (Livak and Schmittgen, 2001). 
 
In vitro migration and invasion assays 
 
 SiHa cells were seeded 2 x105 in 6-well plates and transfected the next day with 
either 100 nM negative control precursor miRNA molecules or miR-218 precursor 
molecules (Ambion) using Lipofectamine 2000 (Invitrogen). FAM-labeled precursor 
molecules were used to check transfection efficiency (Ambion). After 72 hr, migration 
assays were performed, and the cells were seeded onto 24-well Transwell inserts, 8 µm 
pore size (Corning), in media without serum. The lower chambers of the Transwell plate 
were filled with DMEM containing 20% FBS to serve as a chemoattractant.  For invasion 
assays, the Transwell inserts were coated with Matrigel basement membrane extract 
(BD Biosciences). After 24 hr, migratory or invasive cells in the membrane were fixed 
with 100% methanol and then stained with 0.1% crystal violet. The cells were then 
counted under a microscope at 400X magnification. The mean of five fields from six 
separate assays was used. 
 
In vitro wound-healing assays 
 
SiHa cells were seeded 2 x105 in 6-well plates and transfected the next day with 
either 100 nM negative control precursor miRNA molecules or miR-218 precursor 
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molecules (Ambion) using Lipofectamine 2000 (Invitrogen). FAM-labeled precursor 
molecules were used to check transfection efficiency (Ambion). After 48 hr, the cells 
were seeded 2 x105 into 24-well plates and allowed to become confluent overnight. The 
wells were then scratched with a sterile pipette tip creating a lesion approximately 500 
µm in width. The wells were photographed and the wound gap was measured. After 24 
hr, the gap was photographed and measured again. Six independent experiments were 
performed. 
4.3 RESULTS 
HPV-16 E6 regulates miR-218 through p300 
 
Previously we found that HPV-16 E6 reduces the levels of miR-218 in cervical 
carcinoma cells (Martinez et al., 2008). In order to identify the mechanism by which E6 
regulates miR-218, we utilized LXSN vectors encoding either wild-type E6 or mutant E6. 
We obtained the well-characterized mutants L50G, which does not bind E6AP or p53, 
and does not degrade p53, as well as G130V, which shares the same properties as 
L50G but has reduced ability to bind p300/CBP (Sekaric et al., 2008) (Table 6). The 
G130V mutation is located in the second zinc-finger domain of E6 that is essential for 
p300/CBP binding (Patel et al., 1999). The HPV-16 E6 and p300 studies were carried 
out in U2OS cells (Patel et al., 1999) (Zimmermann et al., 1999). We found that in 
U2OS cells wild-type E6 reduced miR-218 as previously shown, as did the mutant  
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Table 6. HPV-16 E6 mutant properties. (Patel et al., 1999) 
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L50G, when compared to the empty vector (Figure 12B). However, no reduction in miR-
218 levels was observed in the presence of the G130V mutant (Figure 12B). These 
results suggest that E6 regulates miR-218 through p300. We next transfected the HPV-
negative cervical carcinoma C-33A cell line, which expresses high levels of miR-218, 
with siRNA molecules against p300 (Figure 12C). MiR-218 expression was reduced 
upon knock-down of p300 (Figure 12F). In addition, SLIT2 and SLIT3 were also reduced 
(Figure 12 D and E). 
 
Histone 3 lysine 27 acetylation activity is essential for miR-218 expression 
  
P300 is a histone acetyltransferase and competes with the histone 
methyltransferase EZH2 for modification of H3K27 in embryonic stem cells (Pasini et 
al., 2010). EZH2 was recently shown to bind to the SLIT2 promoter and inhibit its 
expression in prostate cancer cells (Yu et al., 2010). We sought to determine if EZH2 
might similarly regulate the SLIT genes in cervical cancer cells. We transfected SiHa 
cells, which do not express miR-218, with siRNA molecules against EZH2 (Figure 13A). 
Although SLIT2 expression did not change significantly, SLIT3 and miR-218 expression 
increased upon knock-down of EZH2 (Figure 13B, C, and D). 
We next treated C-33A cells with anacardic acid (AA), which inhibits the 
acetyltransferase activity of p300 and reduces H3K27 acetylation (Pasini et al., 2010).  
SLIT2 expression was not reduced, but both SLIT3 and miR-218 expression was 
reduced after 72 hr of AA treatment (Figure 14 A, B, and C). We also treated SiHa cells 
with adenosine dialdehyde (AdOx), which inhibits EZH2 and reduces H3K27 
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methylation (Miranda et al., 2009). SLIT2 expression did not increase, but both SLIT3 
and miR-218 expression increased after 72 hr of AdOx treatment (Figure 14 D, E, and 
F). 
The SLIT2 and SLIT3 promoters are methylated in cervical cancer (Narayan et 
al., 2006). However, Narayan et al. were unable to reactivate expression of either SLIT 
gene in SiHa and other HPV-positive cervical cancer cell lines following treatment with 
the DNA methyltransferase inhibitor 5-azacytidine (5-aza) or the histone deacetylase 
inhibitor trichostatin A (TSA) either alone or in combination. We treated SiHa cells with 
5-aza, TSA, AdOx, or a combination and observed reactivation of SLIT2, SLIT3, and 
miR-218 expression after 72 hr (Figure 15). These results indicate that H3K27 
acetylation at the SLIT2/3 promoters is important for SLIT and miR-218 expression. 
 
MiR-218 reduces the migration and invasion of HPV-16 positive cervical carcinoma cells 
 
 In order to understand the function of miR-218, we performed a number of 
studies to identify how it might affect the cellular phenotype. We performed cell 
viability/cytotoxicity, proliferation, apoptosis, and cell cycle assays. We did not observe 
any significant differences between cells transfected with negative precursor molecules 
or miR-218 for these assays (data not shown). SLIT2 and SLIT3 are extracellular 
signaling molecules and have been shown to decrease the migration of cancer cells 
(Tseng et al., 2010). We therefore surmised that miR-218 might induce a similar 
phenotype. We performed Transwell migration and Matrigel invasion assays and found 
that miR-218 significantly reduced the migration and invasion of SiHa cervical 
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carcinoma cells (Figure 16). We also performed in vitro wound-healing assays and 
found that miR-218 reduces the ability of SiHa cells to close the gap lesion (Figure 17). 
Finally, we found that miR-218 transfected cells were more adhesive and had reduced 
capacity to grow in non-anchorage dependent conditions (data not shown). 
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Figure 12. p300 regulates miR-218. (A) HPV-16 E6 expression in U2OS cells infected 
with LXSN 16E6 WT or mutant constructs. (B) miR-218 expression in U2OS cells 
infected with 16E6 WT or mutant constructs. (C) p300 expression in C-33A cells 
transfected with siRNA molecules targeting p300. (D) SLIT2 expression in C-33A cells. 
(E) SLIT3 expression in C-33A cells. (F) miR-218 expression in C-33A cells. 
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Figure 13. Reduction in EZH2 increases SLIT2, SLIT3, and miR-218 levels. (A) EZH2 
expression in SiHa cells transfected with siRNA molecules targeting EZH2. (B) SLIT2 
expression. (C) SLIT3 expression. (D) miR-218 expression. 
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Figure 14. SLIT2, SLIT3, and miR-218 expression in cells treated with anacardic acid or 
adenosine dialdehyde. C-33A cells were treated with anacardic acid (AA) for 72 hr. (A) 
SLIT2 expression. (B) SLIT3 expression. (C) miR-218 expression. SiHa cells were 
treated with adenosine dialdehyde (AdOx) for 72hrs. (D) SLIT2 expression. (E) SLIT3 
expression. (F) miR-218 expression. 
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Figure 15. SLIT2, SLIT3, and miR-218 are increased upon treatment with a combination 
of 5-azacytidine, trichostatin A, and adenosine dialdehyde. SiHa cells were treated with 
5-azacytidine (5-aza), trichostatin A (TSA), adenosine dialdehyde (AdOx), or a 
combination for 72 hr. (A) SLIT2 expression. (B) SLIT3 expression. (C) miR-218 
expression. 
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Figure 16. MiR-218 reduces the migration and invasion of SiHa cells. SiHa cells were 
transfected with a negative precursor miRNA molecule or pre-miR-218 for 72 hr. They 
were then seeded on transwell membranes that were either uncoated or coated with 
Matrigel basement membrane extract. After 24 hr, non-migratory cells were removed 
and the migratory cells in the membrane were stained with crystal violet. Six 
independent experiments were performed, and five fields/membrane were counted. 
p<0.05. 
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Figure 17. MiR-218 reduces the in vitro wound-healing capacity of SiHa cells. SiHa cells 
were transfected with a negative precursor miRNA molecule or pre-miR-218 for 72 hr. 
The wells were then scratched with a sterile pipette tip and photographed at 0 hr and 24 
hr post-scratch. Six independent experiments were performed. The gap width/distance 
migrated was measured for each experiment. p<0.05. 
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4.4 DISCUSSION 
We utilized the wild-type HPV-16 E6 protein and its E6 mutants to determine the 
mechanism by which E6 downregulates miR-218. We found that the G130V mutant, 
which is defective in p300-binding, did not reduce miR-218 expression (Figure 12). We 
further found that knock-down of p300 and inhibition of its acetyltransferase activity 
decreases SLIT2, SLIT3, and miR-218 (Figures 12 and 14).  
In addition, knock-down and inhibition of EZH2 increases miR-218 levels 
(Figures 13 and 14). EZH2 is a polycomb group protein and functions in the polycomb 
repressive complex 2 (PRC2). PRC2 proteins EZH2 and SUZ12, and PRC1 proteins 
BMI1, RING1, and RING2, can bind to the SLIT2 promoter (Yu et al., 2010). PRC1 and 
PRC2 are transcriptional repressors that antagonize developmental regulators in 
embryonic stem cells. EZH2 catalyzes the dimethylation and trimethylation of H3K27, 
while p300 catalyzes the acetylation of H3K27 (Pasini et al., 2010). EZH2 has been 
reported to be overexpressed in various cancers (Varambally et al., 2002) (Wagener et 
al., 2008). Interestingly, HPV-16/18 E7 can increase EZH2 expression in cervical cancer 
cells (Holland et al., 2008), thus providing an additional mechanism by which high-risk 
HPVs may target miR-218. In our study, p300 acetyltransferase activity was necessary 
for miR-218 expression. We propose that p300 positively regulates miR-218 expression 
in normal cervical cells. Upon HPV-16 infection, E6 binds p300 and prevents acetylation 
of H3K27, allowing EZH2 to occupy the SLIT2/3 promoters, methylate H3K27, and 
prevent miR-218 expression (Figure 18). 
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SLIT2 and SLIT3 are large genes. SLIT2 is ~365 kb, and SLIT3 is ~635 kb in 
size. SLIT2 harbors miR-218-1 in intron 14, and SLIT3 harbors miR-218-2 in intron 15 
(Figure 18). These miR-218 copies are identical. Because the distance between the 
transcriptional start sites of SLIT2/3 and miR-218-1/2 is large, it is possible that miR-
218-1/2 have their own promoters. However, our work and that of others suggest that 
miR-218-1/2 are processed from the SLIT2/3 transcripts. We previously showed that 
SLIT2 and miR-218 are coordinately expressed in cervical cancer (Martinez et al., 
2008). Others have shown that they are regulated similarly as well (Tie et al., 2010). In 
this study, we found that miR-218 expression closely matches the expression of SLIT2 
and SLIT3. Although SLIT2 did not respond as well as SLIT3 to knock-down of EZH2 
and AdOx treatment, all three behaved similarly when treated in combination with 5-aza, 
TSA, and AdOx (Figure 15). The SLIT2 promoter is hypermethylated in cervical 
carcinoma cells (Narayan et al., 2006), which may account for the greater requirement 
of a combination of the DNA and histone modifying drugs.  
MiR-218 is underexpressed in many cancers including cervical, ovarian, and 
melanomas (Volinia et al., 2006) (Zhang et al., 2006). We showed that miR-218 reduces 
the migration and invasion of cervical carcinoma cells (Figure 16). MiR-218 also 
reduced the in vitro wound-healing capacity of cervical carcinoma cells (Figure 17). 
Others have reported similar findings (Tie et al., 2010) (Song et al., 2010). Based on the 
above results, our work supports the mounting evidence that miR-218 is a tumor 
suppressor miRNA in many cancers.  
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Figure 18. Location of miR-218-1 and miR-218-2 within SLIT2 and SLIT3. MiR218-1 is 
located within intron 14 of SLIT2. MiR-218-2 is located within intron 15 of SLIT3. (Tie et 
al., 2010) 
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Figure 19. Model of miR-218 regulation. In cervical cells, p300 positively regulates 
SLIT2 and SLIT3, as well as miR-218-1/2, which are encoded by the introns of these 
genes. Upon HPV-16 infection, E6 binds to and reduces the HAT activity of p300, 
allowing the repressive histone methyltransferase EZH2, a component of the polycomb 
repressive complex (PRC2), to bind to the SLIT promoters and prevent miR-218 
expression.  
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5.0  CHAPTER 5 
GENERAL DISCUSSION 
 81 
5.1 GENERAL DISCUSSION 
In these studies, we have examined cellular microRNA expression in HPV-16 
positive cervical carcinoma cells. We reported the basal expression level of cellular 
miRNAs in the normal cervix, and we analyzed the expression of cellular miRNAs in 
HPV-16 positive cervical cancer cell lines and tissues compared to the normal cervix. 
We demonstrated that HPV-16 E6 downregulates miR-218 in cervical cancer cells, and 
we identified LAMB3, part of the epithelial-specific protein laminin 5, as a miR-218 
target. Downregulation of miR-218 allows overexpression and deposition of laminin 5 in 
the extracellular matrix where it can serve as a transient receptor for HPVs.  
We further examined cellular miRNAs in cervical dysplasias and cancer, and 
found that miR-218 was underexpressed in these HPV-16 positive cervical dysplasia 
and cancer tissues as well. We provided expression profiles that may be useful as 
biomarkers. We identified MMP3 as an additional target of miR-218. MMP3 is an 
extracellular matrix protein that is overexpressed in cervical cancer (Hagemann et al., 
2007) (Gius et al., 2007), and it is important for the epithelial-mesenchymal transition, 
regulating tumor cell motility and metastasis (Kessenbrock et al., 2010).  
Finally, we demonstrated that HPV-16 E6 regulates miR-218 via the histone 
acetyltransferase p300 in cervical carcinoma cells. We found that p300 knock-down or 
p300 inhibition with anacardic acid reduced miR-218 expression in HPV-negative cells, 
and EZH2 knock-down or its inhibition with adenosine dialdehyde reactivated miR-218 
expression in HPV-16 positive cells. Reactivation was enhanced upon treatment with a 
 82 
combination of 5-azacytidine, trichostatin A, and adenosine dialdehyde. We also 
demonstrated that miR-218 reduces the migration and invasion of cervical cancer cells, 
indicating that miR-218 is a tumor suppressor with potential therapeutic value. 
 
5.2 FUTURE DIRECTIONS 
Future miR-218 directions will include studies to demonstrate binding of p300 
and EZH2 to the SLIT2/3 promoters in cervical carcinoma cells. Although we showed 
that p300 regulates miR-218 expression and antagonizes EZH2, it may not bind directly 
to the SLIT2/3 promoters. ChIP assays could be performed to answer this question.  
Additional studies to identify transcription factors and other key players in this pathway 
may also be performed. 
Analyses to identify additional cellular targets of miR-218 will be performed. SiHa 
cells were transfected with miR-218, and Argonaute 2-containing 
microribonucleoprotein particles (miRNPs) were immunoprecipitated in order to enrich 
for miR-218 and its targets. We eluted the RNA and are in the process of analyzing the 
sample compared to control samples from cells that were not transfected or transfected 
with a negative control molecule via microarray analysis.  
Experiments to identify potential HPV-16 encoded miRNAs are also in progress. 
Viral miRNAs may serve as an efficient method for regulating both viral and cellular 
gene expression. Viral miRNAs were first identified in herpesviruses such as EBV, 
HCMV, KSHV, and HSV-1, which are large DNA viruses characterized by their latent life 
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cycles (Pfeffer et al., 2005) (Cai et al., 2005) (Cui et al., 2006). Polyomaviruses such as 
SV40, JC, and BK viruses are small double-stranded DNA viruses similar to HPVs, and 
they also encode miRNAs (Sullivan et al., 2005). Many of the miRNA-encoding viruses 
are associated with cancer, but to date no HPV-derived miRNAs have been identified.  
We cultured normal immortalized human keratinocytes (NIKS) in an organotypic 
raft system that mimics epithelial tissue. Cells were seeded over a layer of collagen and 
fibroblast feeders assembled on a mesh raft in enriched media. We maintained twelve 
rafts each of HPV-16 infected and non-infected keratinocytes in this manner for ten 
days. This allowed the highly differentiation-dependent HPV-16 to replicate as the cells 
formed differentiated epithelial tissue. The tissues were harvested after ten days 
allowing sufficient time for cellular differentiation and viral gene expression to occur. An 
aliquot of total cell lysates was used to confirm expression of the HPV-16 E6 and E7 
oncogenes in the HPV-positive rafts. We then immunoprecipitated Argonaute 2-
associated miRNP particles using an antibody specific for human Ago2. This step 
greatly reduced the background of non-miRNA small RNAs and RNA breakdown 
products. We eluted RNA from these miRNP particles and confirmed the presence of 
miRNAs by quantitative RT-PCR of let-7 and miR-21. We expect that the small RNAs 
described in HPV-16 infected NIKS will be enriched in HPV-16 encoded miRNAs and 
will also contain any target mRNAs hybridized due to complementarity. The RNA 
fraction may also contain cellular miRNAs and their target mRNAs. We have isolated 
the above RNA fractions from both HPV-16 infected and uninfected cells. The GPCL at 
the University of Pittsburgh has performed deep sequencing of these samples using the 
SOLiD™ 4 System and data analysis is currently in progress. The discovery of HPV-
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encoded miRNAs will increase our knowledge of the oncogenic properties of HPV-16, 
and such miRNAs may also have potential use in the early diagnosis, prognosis and 
treatment of cancer. 
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APPENDIX A 
SUPPLEMENTARY TABLES 
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Supplementary Table 1. Basal expression of miRNAs in the normal cervix 
Human miRNA Median 
hsa_miR_145 12003.5 
hsa_miR_26a 9015.0 
hsa_miR_99a 5937.5 
hsa_let_7a 5205.5 
hsa_miR_143 5135.0 
hsa_let_7b 5034.5 
hsa_let_7c 4859.0 
hsa_miR_125b 4093.0 
hsa_miR_126 3713.5 
hsa_miR_195 3662.5 
hsa_miR_21 3223.5 
hsa_miR_24 3187.5 
hsa_miR_23b 3131.5 
hsa_let_7d 3032.5 
hsa_miR_23a 2995.5 
hsa_miR_16 2777.5 
hsa_miR_100 2596.5 
hsa_miR_27b 2387.0 
hsa_let_7g 2332.0 
hsa_miR_29a 2195.0 
hsa_let_7f 2051.5 
hsa_miR_107 1490.0 
hsa_miR_125a 1401.5 
hsa_miR_103 1392.5 
hsa_miR_221 1374.0 
hsa_let_7i 1369.0 
hsa_miR_199a 1309.0 
hsa_miR_191 1298.0 
hsa_miR_199a_AS 1275.5 
hsa_miR_205 1119.5 
hsa_miR_30d 1074.5 
hsa_miR_22 1049.0 
hsa_miR_30b 1001.5 
hsa_miR_30a_5p 996.5 
hsa_let_7e 905.0 
hsa_miR_10b 812.5 
hsa_miR_222 775.5 
hsa_miR_203 747.0 
hsa_miR_26b 735.0 
hsa_miR_130a 698.0 
hsa_miR_30c 693.0 
hsa_miR_152 652.0 
hsa_miR_497 612.0 
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hsa_miR_148a 605.0 
hsa_miR_368 597.5 
hsa_miR_99b 554.0 
hsa_miR_214 541.0 
hsa_miR_200c 506.5 
hsa_miR_106a 492.5 
hsa_miR_27a 476.5 
hsa_miR_30e_5p 458.5 
hsa_miR_342 449.5 
hsa_miR_10a 427.0 
hsa_miR_19b 408.5 
hsa_miR_17_5p 402.0 
hsa_miR_31 399.0 
hsa_miR_34a 394.0 
hsa_miR_320 386.0 
hsa_miR_133a 378.5 
hsa_miR_200b 350.5 
hsa_miR_15b 348.0 
hsa_miR_451 318.0 
hsa_miR_133b 285.5 
hsa_miR_29b 268.0 
hsa_miR_92 246.0 
hsa_miR_422b 236.5 
hsa_miR_1 229.5 
hsa_miR_15a 222.0 
hsa_miR_196b 211.0 
hsa_miR_93 210.5 
hsa_miR_128b 209.0 
hsa_miR_494 202.5 
hsa_miR_361 202.0 
hsa_miR_199b 196.0 
hsa_miR_223 194.5 
hsa_miR_98 192.0 
hsa_miR_25 186.0 
hsa_miR_200a 185.0 
hsa_miR_106b 184.5 
hsa_miR_28 184.5 
hsa_miR_146a 179.5 
hsa_miR_29c 175.0 
hsa_miR_146b 170.5 
hsa_miR_181a 155.0 
hsa_miR_150 153.0 
hsa_miR_424 142.0 
hsa_miR_495 142.0 
hsa_miR_187 136.5 
hsa_miR_128a 129.5 
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hsa_miR_218 121.5 
hsa_miR_151 113.5 
hsa_miR_20b 113.5 
hsa_miR_503 112.0 
hsa_miR_379 111.0 
hsa_miR_181b 108.5 
hsa_miR_224 108.0 
hsa_miR_185 104.5 
hsa_miR_141 104.0 
hsa_miR_193b 103.0 
hsa_miR_487b 98.0 
hsa_miR_376a 96.0 
hsa_miR_335 95.5 
hsa_miR_455 94.5 
hsa_miR_423 94.0 
hsa_miR_20a 93.5 
hsa_miR_452 77.0 
hsa_miR_189 72.0 
hsa_miR_194 67.5 
hsa_miR_132 60.5 
hsa_miR_126_AS 60.0 
hsa_miR_331 56.5 
hsa_miR_186 54.5 
hsa_miR_130b 47.0 
hsa_miR_139 44.0 
hsa_miR_362 41.0 
hsa_miR_140 40.5 
hsa_miR_382 36.0 
hsa_miR_429 35.5 
hsa_miR_101 35.0 
hsa_miR_210 31.5 
hsa_miR_155 30.5 
hsa_miR_204 30.0 
hsa_miR_148b 28.5 
hsa_miR_182 25.5 
hsa_miR_324_3p 25.0 
hsa_miR_181c 24.0 
hsa_miR_432 24.0 
hsa_miR_500 23.0 
hsa_miR_17_3p 22.0 
hsa_miR_345 22.0 
hsa_miR_542_5p 21.5 
hsa_miR_484 21.0 
hsa_miR_181d 20.5 
hsa_miR_192 20.0 
hsa_miR_188 19.5 
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hsa_miR_363 19.5 
hsa_miR_154 19.0 
hsa_miR_422a 19.0 
hsa_miR_134 18.5 
hsa_miR_425 18.0 
hsa_miR_491 18.0 
hsa_miR_299_3p 17.5 
hsa_miR_34b 17.5 
hsa_miR_511 17.0 
hsa_miR_505 16.5 
hsa_miR_127 16.0 
hsa_miR_142_5p 16.0 
hsa_miR_299_5p 16.0 
hsa_miR_381 16.0 
hsa_miR_202 15.5 
hsa_miR_377 15.5 
hsa_miR_369_5p 14.5 
hsa_miR_409_3p 14.0 
hsa_miR_339 12.5 
hsa_miR_30e_3p 11.5 
hsa_miR_375 11.5 
hsa_miR_493_3p 11.0 
hsa_miR_539 10.5 
hsa_miR_212 10.0 
hsa_miR_376b 10.0 
hsa_miR_198 9.5 
hsa_miR_329 9.5 
hsa_miR_378 9.5 
hsa_miR_18a 8.5 
hsa_miR_213 8.5 
hsa_miR_34c 8.5 
hsa_miR_409_5p 8.5 
hsa_miR_452_AS 8.5 
hsa_miR_9_AS 8.5 
hsa_miR_149 8.0 
hsa_miR_370 8.0 
hsa_miR_502 8.0 
hsa_miR_19a 7.5 
hsa_miR_509 7.5 
hsa_miR_197 7.0 
hsa_miR_323 7.0 
hsa_miR_365 7.0 
hsa_miR_486 7.0 
hsa_miR_95 7.0 
hsa_miR_296 6.5 
hsa_miR_30a_3p 6.5 
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hsa_miR_374 6.5 
hsa_miR_513 6.5 
hsa_miR_518c_AS 6.5 
hsa_miR_18b 6.0 
hsa_miR_363_AS 6.0 
hsa_miR_373_AS 6.0 
hsa_miR_136 5.5 
hsa_miR_138 5.5 
hsa_miR_206 5.5 
hsa_miR_7 5.5 
hsa_miR_340 5.0 
hsa_miR_433 5.0 
hsa_miR_517_AS 5.0 
hsa_miR_193a 4.5 
hsa_miR_196a 4.5 
hsa_miR_492 4.5 
hsa_miR_410 4.0 
hsa_miR_488 4.0 
hsa_miR_514 4.0 
hsa_miR_518f 4.0 
hsa_miR_520a 4.0 
hsa_miR_523 3.5 
hsa_miR_105 3.0 
hsa_miR_18a_AS 3.0 
hsa_miR_200a_AS 3.0 
hsa_miR_301 3.0 
hsa_miR_483 3.0 
hsa_miR_487a 3.0 
hsa_miR_489 3.0 
hsa_miR_493_5p 3.0 
hsa_miR_526a 3.0 
hsa_miR_124a 2.5 
hsa_miR_324_5p 2.5 
hsa_miR_330 2.5 
hsa_miR_518a_2_AS 2.5 
hsa_miR_122a 2.0 
hsa_miR_154_AS 2.0 
hsa_miR_383 2.0 
hsa_miR_501 2.0 
hsa_miR_520d_AS 2.0 
hsa_miR_302a_AS 1.5 
hsa_miR_326 1.5 
hsa_miR_371 1.5 
hsa_miR_431 1.5 
hsa_miR_485_3p 1.5 
hsa_miR_517b 1.5 
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hsa_miR_96 1.5 
hsa_miR_33 1.0 
hsa_miR_346 1.0 
hsa_miR_380_5p 1.0 
hsa_miR_450 1.0 
hsa_miR_453 1.0 
hsa_miR_498 1.0 
hsa_miR_508 1.0 
hsa_miR_512_3p 1.0 
hsa_miR_516_3p 1.0 
hsa_miR_518d 1.0 
hsa_miR_519a 1.0 
hsa_miR_526b 1.0 
hsa_miR_545 1.0 
hsa_miR_142_3p 0.5 
hsa_miR_211 0.5 
hsa_miR_302a 0.5 
hsa_miR_302c_AS 0.5 
hsa_miR_373 0.5 
hsa_miR_384 0.5 
hsa_miR_449 0.5 
hsa_miR_485_5p 0.5 
hsa_miR_496 0.5 
hsa_miR_504 0.5 
hsa_miR_517a 0.5 
hsa_miR_518a 0.5 
hsa_miR_518c 0.5 
hsa_miR_518e 0.5 
hsa_miR_520c 0.5 
hsa_miR_520f 0.5 
hsa_miR_520h 0.5 
hsa_miR_9 0.5 
hsa_miR_129 0.0 
hsa_miR_135a 0.0 
hsa_miR_135b 0.0 
hsa_miR_137 0.0 
hsa_miR_144 0.0 
hsa_miR_147 0.0 
hsa_miR_153 0.0 
hsa_miR_182_AS 0.0 
hsa_miR_183 0.0 
hsa_miR_184 0.0 
hsa_miR_190 0.0 
hsa_miR_191_AS 0.0 
hsa_miR_202_AS 0.0 
hsa_miR_208 0.0 
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hsa_miR_215 0.0 
hsa_miR_216 0.0 
hsa_miR_217 0.0 
hsa_miR_219 0.0 
hsa_miR_220 0.0 
hsa_miR_302b 0.0 
hsa_miR_302b_AS 0.0 
hsa_miR_302c 0.0 
hsa_miR_302d 0.0 
hsa_miR_32 0.0 
hsa_miR_325 0.0 
hsa_miR_328 0.0 
hsa_miR_337 0.0 
hsa_miR_338 0.0 
hsa_miR_367 0.0 
hsa_miR_369_3p 0.0 
hsa_miR_372 0.0 
hsa_miR_376a_AS 0.0 
hsa_miR_380_3p 0.0 
hsa_miR_412 0.0 
hsa_miR_432_AS 0.0 
hsa_miR_448 0.0 
hsa_miR_490 0.0 
hsa_miR_499 0.0 
hsa_miR_506 0.0 
hsa_miR_507 0.0 
hsa_miR_510 0.0 
hsa_miR_512_5p 0.0 
hsa_miR_515_3p 0.0 
hsa_miR_515_5p 0.0 
hsa_miR_516_5p 0.0 
hsa_miR_517c 0.0 
hsa_miR_518b 0.0 
hsa_miR_518f_AS 0.0 
hsa_miR_519b 0.0 
hsa_miR_519c 0.0 
hsa_miR_519d 0.0 
hsa_miR_519e 0.0 
hsa_miR_519e_AS 0.0 
hsa_miR_520a_AS 0.0 
hsa_miR_520b 0.0 
hsa_miR_520d 0.0 
hsa_miR_520e 0.0 
hsa_miR_520g 0.0 
hsa_miR_521 0.0 
hsa_miR_522 0.0 
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hsa_miR_524 0.0 
hsa_miR_524_AS 0.0 
hsa_miR_525 0.0 
hsa_miR_525_AS 0.0 
hsa_miR_526b_AS 0.0 
hsa_miR_526c 0.0 
hsa_miR_527 0.0 
hsa_miR_542_3p 0.0 
hsa_miR_544 0.0 
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Supplementary Table 2. MiRNAs differentially expressed in individual HPV-16 positive 
cell lines compared to the normal cervix 
  CaSki SiHa 20863 20861 201402 
MiRNA Fold Fold Fold Fold Fold 
Overexpressed      
hsa_miR_141     10.11 
hsa_miR_210     8.01 
hsa_miR_31     7.81 
hsa_miR_18a     7.80 
hsa_miR_34c     7.37 
hsa_miR_183  8.14   6.37 
hsa_miR_136     5.66 
hsa_miR_301     5.30 
hsa_miR_182     5.18 
hsa_miR_193a     4.82 
Underexpressed      
hsa_miR_126    -26.24 -23.42 
ambi_miR_7029     -13.66 
hsa_miR_451    -12.05 -10.45 
hsa_miR_133b     -10.24 
hsa_miR_495    -8.16 -9.93 
hsa_miR_146a     -8.71 
hsa_miR_223     -8.36 
hsa_miR_195   -18.17  -8.34 
hsa_miR_218     -8.11 
hsa_miR_133a   -10.12  -8.08 
hsa_miR_199b  -19.52   -8.05 
hsa_miR_1     -8.01 
hsa_miR_497     -7.68 
hsa_miR_487b     -7.21 
hsa_miR_145 -51.55 -28.05 -35.46 -11.68 -7.02 
hsa_miR_368   -16.60  -6.91 
hsa_miR_150     -5.90 
hsa_miR_382     -5.51 
ambi_miR_7070     -4.98 
hsa_miR_139     -4.80 
hsa_miR_154     -4.63 
hsa_miR_155     -4.23 
hsa_miR_143  -22.61    
hsa_miR_199a   -14.74   
hsa_miR_214   -12.13   
The q value of all miRNAs was 0. 
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Supplementary Table 3. MiRNAs differentially expressed in the HPV-18 positive cell line 
HeLa compared to the normal cervix 
 HeLa 
MiRNA Fold 
Overexpressed  
ambi_miR_13143 320.8 
hsa_miR_31 13.7 
hsa_miR_106a 12.2 
hsa_miR_93 8.9 
ambi_miR_9630 7.1 
hsa_miR_17_5p 6.6 
hsa_miR_182 6.5 
hsa_miR_196a 6.2 
hsa_miR_30a_5p 5.6 
hsa_miR_183 5.2 
hsa_miR_25 4.5 
hsa_miR_106b 4.4 
hsa_miR_224 3.6 
Underexpressed  
hsa_miR_1 -9.3 
hsa_miR_145 -9.1 
ambi_miR_7029 -8.4 
hsa_miR_205 -8.0 
hsa_miR_133b -7.6 
hsa_miR_143 -6.8 
hsa_miR_214 -6.7 
hsa_miR_199a -5.7 
hsa_miR_368 -5.6 
hsa_miR_451 -5.3 
hsa_miR_329 -4.6 
hsa_miR_200a -4.6 
hsa_miR_200c -3.7 
hsa_miR_139 -3.3 
The q value of all miRNAs was 0. 
 
 96 
Supplementary Table 4. MiRNAs differentially expressed in individual HPV-16 positive 
cell lines compared to the HPV-negative cell line C-33A 
  CaSki SiHa 20863 20861 201402 
MiRNA Fold Fold Fold Fold Fold 
Overexpressed      
hsa_miR_205   50.15 24.19 46.30 
hsa_miR_200c   36.05 21.68 33.59 
hsa_miR_141   16.84 22.42 31.48 
hsa_miR_203   14.69 16.42 30.52 
hsa_miR_34a  8.08  9.19 16.64 
ambi_miR_13258   7.98 9.34 13.14 
hsa_miR_193b  55.41 10.59 8.65 10.82 
hsa_miR_31  10.00 10.90  10.69 
hsa_miR_200b   7.00 6.16 9.35 
hsa_miR_200a   5.35  8.48 
hsa_miR_503  6.02  5.54 7.25 
hsa_miR_224   5.12 5.94 7.16 
hsa_miR_199a     6.85 
hsa_miR_199a_AS     6.63 
hsa_miR_34c     6.53 
hsa_miR_210  8.88   6.35 
hsa_miR_27a  8.85   5.35 
hsa_miR_29b     4.94 
hsa_miR_193a     4.81 
hsa_miR_27b  6.18   4.59 
hsa_miR_422b     4.53 
hsa_miR_34b     4.44 
hsa_miR_145     4.24 
hsa_miR_18a     4.05 
hsa_miR_15a     3.93 
hsa_miR_143     3.92 
hsa_miR_136     3.54 
ambi_miR_3046  29.34    
ambi_miR_12902  14.75    
hsa_miR_24  11.66    
hsa_miR_125a  10.86    
ambi_miR_13268  10.67    
hsa_miR_181b  10.42    
hsa_miR_99b  8.26    
hsa_miR_23b  7.58    
hsa_miR_23a  7.26    
hsa_miR_152  6.90    
Underexpressed      
hsa_miR_99a -19.37     
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hsa_miR_138    -8.50  
The q value of all miRNAs was 0. 
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Supplementary Table 5. MiRNAs differentially expressed in the HPV-18 positive cell line 
HeLa compared to C-33A 
 HeLa 
MiRNA Fold 
Overexpressed  
ambi_miR_13143 99.5 
hsa_let_7i 16.5 
hsa_miR_31 13.7 
hsa_miR_34a 11.4 
hsa_miR_193b 10.3 
hsa_miR_224 7.7 
The q value of all miRNAs was 0. 
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Supplementary Table 6. Probable targets of miRNAs. Computationally predicted targets 
were obtained from the miRBase Target database and cross-referenced with gene 
expression data obtained from Human Genome U133A 2.0 Arrays (Affymetrix) 
MiRNA 
Number of 
targets Probable Targets 
miR-145 13 
ADRM1, BAX, CENPA, DHCR7, GCSH, MRPS18B, 
NPM3, NUDT1, OGG1, POP5, SLC25A11, SNRPB, 
SSSCA1 
miR-143 9 
C1QBP, CDC2, F12, HMBS, SNRPB, SSBP1, 
STIP1, TP53, TUBB4 
miR-368 13 
BUB3, BYSL, HADH2, HRAS, ID1, KCNG1, MCM2, 
MT1X, NEFH, PLK1, SSBP1, TFAP2A, TPX2 
miR-497 14 
ABCF2, ARHGDIA, CHEK1, CLPP, FARSLA, 
HMBS, MRPL40, NDUFS6, OIP5, PMM1, POLR2E, 
PPIE, TUBA1, ZNHIT1 
miR-218 17 
ABCF2, DUSP5, EBP, EFEMP1, EFNA1, HSPA2, 
KRT6B, LAMB3, MBNL2, MRPS27, MT1G, NUP93, 
PLAUR, PPIE, RGS20, SPINT2, TPM1 
miR-200c 16 
APBB2, CNN3, CRYZ, DDAH1, DNAJC8, FKBP1B, 
GRSF1, GSTA4, HSPD1, MAGEA12, RGS5, 
SCG2, SLIT2, TAF12, TCF8, ZNF6 
 
 
 
 
 
 
 
. 
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APPENDIX B 
SUPPLEMENTARY FIGURES 
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Supplementary Figure 1. MiRNA expression data in HeLa, C-33A, and normal cervical 
tissue. For Northern blot analysis, the housekeeping splicing-related small U6 RNA was 
used as a loading control. For real-time qRT-PCR analysis, RNU43 served as the 
endogenous control for miRNAs. 
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